WO2024073673A1 - Modulators of cd1 protein binding to t cell receptors - Google Patents
Modulators of cd1 protein binding to t cell receptors Download PDFInfo
- Publication number
- WO2024073673A1 WO2024073673A1 PCT/US2023/075526 US2023075526W WO2024073673A1 WO 2024073673 A1 WO2024073673 A1 WO 2024073673A1 US 2023075526 W US2023075526 W US 2023075526W WO 2024073673 A1 WO2024073673 A1 WO 2024073673A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- disease
- skin
- pharmaceutically acceptable
- inflammatory
- Prior art date
Links
- 230000027455 binding Effects 0.000 title description 33
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title description 29
- 108091008874 T cell receptors Proteins 0.000 title description 28
- 108090000623 proteins and genes Proteins 0.000 title description 16
- 102000004169 proteins and genes Human genes 0.000 title description 15
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims description 163
- 125000003342 alkenyl group Chemical group 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 42
- 208000027866 inflammatory disease Diseases 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- 206010000496 acne Diseases 0.000 claims description 19
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 18
- 208000003251 Pruritus Diseases 0.000 claims description 16
- 201000004681 Psoriasis Diseases 0.000 claims description 15
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 206010012442 Dermatitis contact Diseases 0.000 claims description 10
- 208000010247 contact dermatitis Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 208000010668 atopic eczema Diseases 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 8
- 208000024780 Urticaria Diseases 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 241000159243 Toxicodendron radicans Species 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 6
- 235000014150 Myroxylon pereirae Nutrition 0.000 claims description 5
- 244000302151 Myroxylon pereirae Species 0.000 claims description 5
- 239000002085 irritant Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims description 4
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims description 4
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims description 4
- 206010001766 Alopecia totalis Diseases 0.000 claims description 4
- 206010001767 Alopecia universalis Diseases 0.000 claims description 4
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 4
- 206010014201 Eczema nummular Diseases 0.000 claims description 4
- 206010015218 Erythema multiforme Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 4
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000004631 alopecia areata Diseases 0.000 claims description 4
- 208000032775 alopecia universalis congenita Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 231100000021 irritant Toxicity 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 230000001823 pruritic effect Effects 0.000 claims description 4
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims description 4
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 208000018191 liver inflammation Diseases 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 208000021510 thyroid gland disease Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 206010037083 Prurigo Diseases 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- -1 lipid compounds Chemical class 0.000 abstract description 13
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 76
- 210000003491 skin Anatomy 0.000 description 76
- 210000001744 T-lymphocyte Anatomy 0.000 description 69
- 150000002632 lipids Chemical class 0.000 description 58
- 235000002639 sodium chloride Nutrition 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 36
- 239000007858 starting material Substances 0.000 description 29
- 201000010099 disease Diseases 0.000 description 25
- 239000003446 ligand Substances 0.000 description 23
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 239000000427 antigen Substances 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 125000000217 alkyl group Chemical group 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000005867 T cell response Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 13
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 238000011830 transgenic mouse model Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 229960002751 imiquimod Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 229940125773 compound 10 Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 150000002190 fatty acyls Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- ZVDBUOGYYYNMQI-UHFFFAOYSA-N dodec-1-yne Chemical compound CCCCCCCCCCC#C ZVDBUOGYYYNMQI-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000001821 langerhans cell Anatomy 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 229960004784 allergens Drugs 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 108010074109 interleukin-22 Proteins 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000004576 lipid-binding Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- PGVRSPIEZYGOAD-UHFFFAOYSA-N 10-bromodecanoic acid Chemical compound OC(=O)CCCCCCCCCBr PGVRSPIEZYGOAD-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229940060265 aldara Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011461 current therapy Methods 0.000 description 3
- ILLHQJIJCRNRCJ-UHFFFAOYSA-N dec-1-yne Chemical compound CCCCCCCCC#C ILLHQJIJCRNRCJ-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003481 dermatitic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003248 quinolines Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YYKBWYBUCFHYPR-UHFFFAOYSA-N 12-bromododecanoic acid Chemical compound OC(=O)CCCCCCCCCCCBr YYKBWYBUCFHYPR-UHFFFAOYSA-N 0.000 description 2
- PFNCOYVEMJYEED-UHFFFAOYSA-N 16-bromohexadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCBr PFNCOYVEMJYEED-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- BKJFDZSBZWHRNH-UHFFFAOYSA-N 8-bromooctanoic acid Chemical compound OC(=O)CCCCCCCBr BKJFDZSBZWHRNH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101710175243 Major antigen Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229940043259 farnesol Drugs 0.000 description 2
- 229930002886 farnesol Natural products 0.000 description 2
- 125000001924 fatty-acyl group Chemical group 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- DZEFNRWGWQDGTR-UHFFFAOYSA-N tetradec-1-yne Chemical compound CCCCCCCCCCCCC#C DZEFNRWGWQDGTR-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 2
- 150000004669 very long chain fatty acids Chemical class 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 125000006605 Cn-m alkenyl group Chemical group 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000610628 Trichoptilium incisum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000009963 fulling Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- RPAWVEMNAJPPEL-UHFFFAOYSA-N morpholine;thiomorpholine Chemical compound C1COCCN1.C1CSCCN1 RPAWVEMNAJPPEL-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- AXIPBRXJGSXLHF-UHFFFAOYSA-N piperidine;pyrrolidine Chemical compound C1CCNC1.C1CCNCC1 AXIPBRXJGSXLHF-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960004631 tixocortol Drugs 0.000 description 1
- YWDBSCORAARPPF-VWUMJDOOSA-N tixocortol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CS)[C@@H]4[C@@H]3CCC2=C1 YWDBSCORAARPPF-VWUMJDOOSA-N 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
Definitions
- This disclosure relates to lipid compounds, and in particular to synthetic derivatives of sphingosine and unsaturated very long chain fatty acids (VLCFA) useful in treating inflammatory diseases, where CD1 proteins are implicated, such as inflammatory diseases of the skin.
- VLCFA very long chain fatty acids
- Inflammatory skin diseases present a significant socioeconomic burden. Acne, contact dermatitis, atopic dermatitis, and psoriasis remain highly prevalent skin diseases that are only partially treated by current therapies, including those with non-specific effects on the immune system and skin, creating unwanted side effects. Spending on dermatitis and acne therapies exceeds 28 billion dollars per year worldwide and is constantly increasing. In a similar manner, psoriasis is a chronic, immune-mediated, inflammatory skin disease with a profound impact on patients’ quality of life. Psoriasis and acne may lead to social isolation, anxiety, distress and reduced self-esteem. Psoriasis patients experience a range of symptoms including itching and plaque-related pain.
- CD 1 -restricted T cells have been implicated in inflammatory conditions such as psoriasis, atopic dermatitis, and contact dermatitis.
- CD 1 -restricted T cells recognize lipid antigens and can be divided into 2 groups, group 1 CD1 (CD la, b, c)-restricted and group 2 CD Id-restricted T cells (NKT cells).
- the present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 is as described herein.
- the present disclosure provides a compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is as described herein.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is suitable for topical administration.
- the present disclosure provides a method of preventing or treating an inflammatory disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same.
- the inflammatory disease is an inflammatory skin disease.
- FIG. 1 contains a schematic showing T cell receptors binding peptide-MHC or lipid- CD1 complexes.
- FIG. 2 contains a schematic showing natural lipids binding CD la and blocking T cell response.
- FIG. 3 shows that the long chain doubly unsaturated sphingomyelin (42:2 SM) binds CD la with its phosphocholine headgroup protruding, which blocks approach of T cell receptors (42:2 SM).
- the more common short chain 36:2 SM binds by tucking its phosphocholine group largely inside CD la so T cell receptors can approach CD la and are not blocked.
- FIG. 4 shows that sulfatide lipid compound with a green and yellow head group forms complex with CD la. Sulfatide sits similarly within CD la as compared to other lipids, but the sulfatide headgroup alters the protein surface of CD la and protrudes to the outer surface of CD la where it can block T cell receptors.
- FIG. 5 shows inhibition of CD la binding to human T cells in vitro.
- Exemplified sphingomyelins block CDla protein binding to RCS36 T cells.
- Fluorescent human CDla tetramers were treated with media (mock) or a sphingomyelin variant synthesized with the indicated fatty chain and tested for staining of human CD la autor eactive T cells using flow cytometry.
- the fatty acyl group is conjugated to a Cl 8: 1 sphingosine unit.
- the C28: 1 fatty acyl group and the Cl 8: 1 sphingosine group constitute C46:2 sphingomyelin (compound 10).
- FIG. 6 shows sphingomyelin intervention model to modulate skin inflammation in vivo.
- Sphingomyelin species C34:l, C42:2 or C46:2 (20pg/20pl ethanol), or vehicle alone (20pl ethanol) were applied topically to WT or CD la transgenic mouse ear skin at 48 hour intervals before and during application of Aldara on days 0-5 (20 mg 5% imiquimod cream).
- FIG. 7 shows that application of long chain sphingomyelins in vivo reduces imiquimod-induced skin thickening.
- N 2-3, 2-way-ANOVA with Dunnett’s test, *, P ⁇ 0.05; ****, P ⁇ 0.0001 indicates significance on comparison to “CDla:EtOH” at day 7, mean ⁇ SD).
- FIG. 8 shows that application of very long chain sphingomyelins in vivo reduces imiquimod-induced skin inflammation.
- WT wild-type
- CD la CD la transgenic mouse ear skin
- FIG. 9A shows the impact of sphingomyelin application on the imiquimod-induced cutaneous cellular immune response.
- WT wild-type
- CD la CD la transgenic mice
- 20 pg sphingomyelin SM34:1, SM42:2 or SM46:2
- Skin T cell and draining lymph node T cell, frequency was determined.
- lymph node CD4 and CD8 T cells assessed for cell surface CD69 expression, which is an indication of T cell activation. Skin and draining LN eosinophil and neutrophil frequency was determined.
- FIG. 9B shows the impact of sphingomyelin application on the imiquimod-induced cutaneous cytokine-based immune response. Skin cytokine levels were assessed on day 7 of imiquimod-treated wild-type (WT) and CD la transgenic mice (CD la) treated topically with 20pg sphingomyelin (SM34: 1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6, as measured by cytometric bead array.
- WT wild-type
- CD la CD la transgenic mice
- 20pg sphingomyelin SM34: 1, SM42:2 or SM46:2
- FIG. 10 shows the impact of sphingomyelin application on the imiquimod- induced systemic immune response.
- N 2-3, 1-way-ANOVA with Dunnett’s test, *, P ⁇ 0.05; **, P ⁇ 0.01, mean ⁇ SD).
- FIG. 11 show the impact of sphingomyelin application on MC903 type 2 inflammation and clinical itch.
- the ears of hCDla and WT mice were topically treated with Inmol MC903 /EtOH on days 0, 2 and 5.
- 20ug/20ul of SM 46:2, SM 42:2, SM 34: 1 and vehicle were applied on the ear tissue on days -2, 0, 2 and 4.
- (A) Ear thickness, and (B) itching frequency were evaluated at endpoint of day 6.
- CD1 proteins are expressed locally in defined tissues, such as the skin, where they bind lipids that activate human T cells to cause inflammation.
- the present disclosure is based, at least in part, on the realization that synthetic lipids such as those within the present claims bind CD1 but block activation of T cells, which effectively treats skin inflammation.
- T cells recognize millions of antigens using rearranged and clonally distributed T cell receptors (TCRs).
- TCRs T cell receptors
- Activated T cells are the central effectors of many types of human immune response, as they orchestrate the actions of other T cells, B cells, dendritic cells and Natural Killer (NK) cells that are key causes of human autoimmune diseases.
- TCRs control T cell activation, which occurs in response to peptide antigens presented by highly polymorphic Major Histocompatibility Complex (MHC) proteins (See FIG. 1, left). Because MHC genes are polymorphic, MHC antigen presenting proteins differ in their structure from person to person.
- MHC Major Histocompatibility Complex
- CD1 proteins bind lipids (See FIG. 1, right), whereas MHC I and II bind and display peptides.
- lipid ligands of CD1 proteins have not been as broadly described and implemented as modulators of T cell function.
- T cell antigen receptors provide strong, primary signals that control the activation, de-activation or death of T cells.
- the lipidic compounds within the present claims modulate T cell autoimmunity by modulating T cell receptor contact with non-polymorphic CD1 proteins.
- Engineering lipid ligands that efficiently bind CD1 proteins and broadly block TCR binding and activation could selectively inhibit CD1- reactive T cells without substantially changing other aspects of the immune system.
- CD1 antigen presenting proteins The four types of human CD1 antigen presenting proteins, CD la, CD lb, CDlc and CD Id, are expressed at high density on dendritic cells, macrophages, and B cells, which are the major antigen presenting cells in the human body.
- CD1 proteins bind many types of lipids to form complexes that engage T cell receptors (e.g., aPTCRs or ySTCRs) leading to T cell activation.
- CD la, CD lb, CDlc and CD Id proteins each have a distinct lipid binding clefts that accommodate differing patterns of lipid ligands.
- Newly synthesized CD1 proteins fold in the endoplasmic reticulum, where they capture lipids and traffic as CD 1 -lipid complexes through the secretory pathway to the cell surface.
- a cohort of CD1 proteins on a given cell bind diverse lipids, which generates CD1 lipid complexes that either do or do not bind to the major activating receptors on T cells known as o.p T cell receptors or y5 T cell receptors.
- CD1 proteins can capture self or foreign lipids for display to T cells.
- CD1 ligands use their aliphatic hydrocarbon tails, also known as lipid anchors, to bind within a hydrophobic cleft in CD1. This mode of binding allows the carbohydrate, sulfate, choline or other hydrophilic head groups to protrude to the surface of CD1 (See FIG. 1).
- the TCR can recognize an epitope that is formed by the surface of CD1 itself (i.e., CD1 autoreactive T cells) or by a combination of the CD1 protein and the protruding head group of each lipid antigen (lipid reactive T cell).
- Most previously studied lipid ligands of CD1 were discovered in activation assays and have activating properties for T cells. Without being bound to any particular theory, the CD1 ligands described in this application were discovered through binding assays. Therefore, the ligands reported have particularly strong CD1 binding properties, but can lead to activation, no effect, or blockade of functional T cell responses.
- the compounds and methods of this disclosure advantageously block the binding and interaction between CD1 and lipid-reactive TCRs, thereby blocking the activation response of TCRs that directly bind to outer surface of CD1 proteins in the absence of any lipid antigen (See Figure 2).
- the chemical design and synthetic production of antigens with longer and unsaturated alkyl chains allows stronger binding of synthetic analogs to CD1 proteins.
- the longer alkyl chains position the hydrophilic head groups so that they protrude more extensively from the surface of CD1, which allows dominant negative inhibition of CD1 to many types TCRs that might otherwise bind to CD1.
- CD1 proteins The four types of CD1 proteins, CD la, CD lb, CDlc and CD Id, are expressed on the major antigen presenting cell types found throughout the human body, including dendritic cells, B cells, macrophages and thymocytes. All four types of human CD1 proteins activate both a and y5 T cells from the blood, demonstrating systemic immune responses. Further, through study of human T cells, CD Id knockout mice or human CD la transgenic mice, there is clear and credible evidence for CD 1 -mediated T cell response to viral, fungal and bacterial infections, as well as models of autoimmune diseases, anticancer response and T cell mediated drug interactions.
- each type of CD1 protein has a distinctly shaped ligand binding groove.
- Each CD1 protein type shows distinct patterns of expression in the human body. For example, skin shows highest expression of CD la, whereas gut and liver show highest expression of CD Id. All four human CD1 isoforms activate human T cells that circulate in the blood. The current examples discussed in this proposal emphasize one case in which CD la is expressed at high levels in skin, and CD la ligands are applied topically in skin. However, CD lb, CDlc and CD Id can also be expressed in human skin, and CD la is expressed in other organs in the body.
- lipid ligands that bind any of the four types of human CD1 antigen presenting molecules can be developed as immune regulators and applied using enteral, parenteral, topical, intradermal, mucosal or other routes.
- T cell autoreactivity toward human CD1 proteins is known for human CD la, CD lb, CDlc, and CD Id.
- the frequency of CD la autoreactive T cells in the blood and skin is particularly high, when measured using limiting dilution cloning, single cell ELISA or tetramer assays.
- Lipid-loaded CD1 tetramers are oligomerized antigen presenting molecules that directly detect binding of TCRs to measure the rate of T cell response to any defined antigen or antigen presenting molecule.
- CD la tetramerbinding T cells are about 100-fold more frequent than CD lb tetramer-binding T cells, and CD la autoreactive tetramer+ T cells account for approximately 1 % of total T cells on average and range to more than 20 percent in selected donors.
- CD la proteins are expressed at high density in skin, where they are found on myeloid dendritic cells and at particularly high density on Langerhans cells (LCs).
- LCs Langerhans cells
- self-antigens for CD la are extracted from skin in larger amounts than from other tissues.
- CD la autoreactive T cells The abundance of CD la autoreactive T cells, CD la protein and CD la- presented antigens raises basic questions about possible mechanisms of inhibition of CD la autoreactivity, which might otherwise result in autoimmune disease (See FIG. 2). Indeed, recent studies show that CD la autoreactive T cells are present at higher levels in human skin involved with atopic dermatitis and psoriasis, as compared to skin from healthy donors or non-involved skin. Also, common allergens such as house dust mites contain phospholipase activity and generate lysolipids that bind to CD la and contribute to T- intradermal cell response.
- squalene which is a common lipid whose overproduction in acne syndromes (common acne, acne vulgaris), has been identified as a CD la presented autoantigen.
- transgenic expression of human CD la in mouse skin results in marked augmentation of immune response to the contact dermatitis antigen, urushiol (poison ivy) as well as the TLR agonist imiquimod, which is widely used as a model of psoriasiform and dermatitic skin inflammation.
- the present disclosure provides compounds that specifically block interaction of a CD la protein and T cell receptors, which in turn blocks CD la- mediated T cell response or inflammation both in vitro and in vivo.
- Pharmaceutical compositions including these compounds e.g., for topical application to skin
- methods of using these compounds and compositions e.g., for treating skin inflammatory diseases are also provided.
- the compositions of matter and synthetic approaches for molecules described in this disclosure generate compounds that are both more homogenous and chemically different from the structures of endogenous lipids normally present in skin.
- the present application provides a compound of Formula
- R 1 is C19-37 alkenyl. In some embodiments, R 1 is C20-41 alkenyl. In some embodiments, R 1 is C21-37 alkenyl. In some embodiments, R 1 is C22-41 alkenyl. In some embodiments, R 1 is C23-37 alkenyl. In some embodiments, R 1 is C24-41 alkenyl. In some embodiments, R 1 is C25-37 alkenyl. In some embodiments, R 1 is C26-41 alkenyl. In some embodiments, R 1 is C27-37 alkenyl. In some embodiments, R 1 is C28-41 alkenyl. In some embodiments, R 1 is C29-37 alkenyl.
- R 1 is C30-41 alkenyl. In some embodiments, R 1 is C31-37 alkenyl. In some embodiments, R 1 is C32-41 alkenyl. In some embodiments, R 1 is C27 alkenyl. In some embodiments, R 1 is C28 alkenyl. In some embodiments, R 1 is C29 alkenyl. In some embodiments, R 1 is C30 alkenyl. In some embodiments, R 1 is C31 alkenyl. In some embodiments, R 1 is C32 alkenyl. In some embodiments, R 1 is C33 alkenyl. In some embodiments, R 1 is C34 alkenyl. In some embodiments, R 1 is C35 alkenyl. In some embodiments, R 1 is C36 alkenyl. In some embodiments, R 1 is C37 alkenyl. In some embodiments, R 1 is C38 alkenyl. In some embodiments, R 1 is C40 alkenyl.
- any of said alkenyl groups comprises 2 double bonds. In some embodiments, the 2 double bonds are conjugated. In some embodiments, the 2 double bonds are not conjugated. In some embodiments, any of said alkenyl groups comprises 1 double bond.
- any of the double bonds is at C9, Cll, C13, C15, C17, or Cl 9 in the alkenyl group of R 1 .
- the double bond is at C9.
- the double bond is at Cll.
- the double bond is at Cl 3.
- the double bond is at Cl 5.
- the double bond is at Cl 7.
- the double bond is at Cl 9.
- any of the double bonds is Z configuration.
- any of the double bonds is E configuration.
- the alkenyl group of R 1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in E configuration.
- the alkenyl group of R 1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 2 double bonds each in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 2 double bonds each in E configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in E configuration and 1 double bond in Z configuration.
- the compound of Formula (I) has formula: or a pharmaceutically acceptable salt thereof.
- the compound of Formula (I) has formula: or a pharmaceutically acceptable salt thereof, wherein x and y are as described herein.
- x is an integer from 3 to 13 and y is an integer from 6 to 26.
- x is an integer from 3 to 13 and y is an integer from 16 to 26.
- x is an integer from 3 to 13 and y is an integer from 6 to 16.
- x is an integer from 3 to 13 and y is an integer from 8 to 16.
- x is 3, 5, 7, 9, or 11.
- x is 3.
- x is 5.
- x is 7.
- x is 9.
- x is 11. In some embodiments, y is from 0 to 26. In some embodiments, y is 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26. In some embodiments, x is 3, and y is from 8 to 26. In some embodiments, x is 3 and y is from 16 to 26. In some embodiments, x is 5, and y is from 6 to 24. In some embodiments, x is 5 and y is from 14 to 24. In some embodiments, x is 7, and y is from 4 to 22. In some embodiments, x is 5 and y is from 12 to 22. In some embodiments, x is 9, and y is from 2 to 20. In some embodiments, x is 5 and y is from 10 to 20.
- x is 11, and y is from 2 to 20.
- the hydrocarbon chain comprising x and y comprises at least 19 and no more than 41 carbon atoms. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 27 and no more than 41 carbon atoms.
- the compounds or Formula (I) are selected from any one of the following compounds in Table 1.
- the compound of Formula (I) has formula:
- the compound of Formula (I) has formula: or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a compound selected from:
- the present application provides a compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is as described herein.
- R 1 is C19-37 alkenyl. In some embodiments, R 1 is C20-41 alkenyl. In some embodiments, R 1 is C21-37 alkenyl. In some embodiments, R 1 is C22-41 alkenyl. In some embodiments, R 1 is C23-37 alkenyl. In some embodiments, R 1 is C24-41 alkenyl. In some embodiments, R 1 is C25-37 alkenyl. In some embodiments, R 1 is C26-41 alkenyl. In some embodiments, R 1 is C27-37 alkenyl. In some embodiments, R 1 is C28-41 alkenyl. In some embodiments, R 1 is C29-37 alkenyl.
- R 1 is C30-41 alkenyl. In some embodiments, R 1 is C31-37 alkenyl. In some embodiments, R 1 is C32-41 alkenyl. In some embodiments, R 1 is C27 alkenyl. In some embodiments, R 1 is C28 alkenyl. In some embodiments, R 1 is C29 alkenyl. In some embodiments, R 1 is C30 alkenyl. In some embodiments, R 1 is C31 alkenyl. In some embodiments, R 1 is C32 alkenyl. In some embodiments, R 1 is C33 alkenyl. In some embodiments, R 1 is C34 alkenyl. In some embodiments, R 1 is C35 alkenyl.
- R 1 is C36 alkenyl. In some embodiments, R 1 is C37 alkenyl. In some embodiments, R 1 is C38 alkenyl. In some embodiments, R 1 is C40 alkenyl.In some embodiments, R 1 is C19 alkenyl. In some embodiments, R 1 is C20 alkenyl. In some embodiments, R 1 is C21 alkenyl. In some embodiments, R 1 is C22 alkenyl. In some embodiments, R 1 is C23 alkenyl. In some embodiments, R 1 is C24 alkenyl. In some embodiments, R 1 is C25 alkenyl. In some embodiments, R 1 is C26 alkenyl.
- R 1 is C27 alkenyl. In some embodiments, R 1 is C28 alkenyl. In some embodiments, R 1 is C29 alkenyl. In some embodiments, R 1 is C30 alkenyl. In some embodiments, R 1 is C31 alkenyl. In some embodiments, R 1 is C32 alkenyl. In some embodiments, R 1 is C33 alkenyl. In some embodiments, R 1 is C34 alkenyl. In some embodiments, R 1 is C35 alkenyl. In some embodiments, R 1 is C36 alkenyl. In some embodiments, R 1 is C38 alkenyl. In some embodiments, R 1 is C40 alkenyl.
- any of said alkenyl groups comprises 2 double bonds. In some embodiments, the 2 double bonds are conjugated. In some embodiments, the 2 double bonds are not conjugated. In some embodiments, any of said alkenyl groups comprises 1 double bond.
- any of the double bonds is at C9, Cll, C13, C15, C17, or Cl 9 in the alkenyl group of R 1 .
- the double bond is at C9.
- the double bond is at Cll.
- the double bond is at Cl 3.
- the double bond is at Cl 5.
- the double bond is at Cl 7.
- the double bond is at Cl 9.
- the alkenyl group of R 1 has one double bond at C9, Cll, C13, C15, C17, or C19. In some embodiments, the alkenyl group of R 1 has double bonds at two of C9, Cll, C13, C15, C17, and C19.
- any of the double bonds is Z configuration. In some embodiments, any of the double bonds is E configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in E configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 2 double bonds each in Z configuration. In some embodiments, the alkenyl group of R 1 comprises 2 double bonds each in E configuration. In some embodiments, the alkenyl group of R 1 comprises 1 double bond in E configuration and 1 double bond in Z configuration.
- the compound of Formula (II) has formula: or a pharmaceutically acceptable salt thereof.
- the compound of Formula (II) has formula: or a pharmaceutically acceptable salt thereof, wherein x and y are as described herein.
- x is an integer from 3 to 13 and y is an integer from 6 to 26.
- x is an integer from 3 to 13 and y is an integer from 16 to 26.
- x is an integer from 3 to 13 and y is an integer from 6 to 16.
- x is an integer from 3 to 13 and y is an integer from 8 to 16.
- x is 3, 5, 7, 9, or 11.
- x is 3.
- x is 5.
- x is 7.
- x is 9.
- x is 11. In some embodiments, y is from 0 to 26. In some embodiments, y is 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26. In some embodiments, x is 3, and y is from 8 to 26. In some embodiments, x is 3 and y is from 16 to 26. In some embodiments, x is 5, and y is from 6 to 24. In some embodiments, x is 5 and y is from 14 to 24. In some embodiments, x is 7, and y is from 4 to 22. In some embodiments, x is 5 and y is from 12 to 22. In some embodiments, x is 9, and y is from 2 to 20. In some embodiments, x is 5 and y is from 10 to 20.
- x is 11, and y is from 2 to 20.
- the hydrocarbon chain comprising x and y comprises at least 19 and no more than 41 carbon atoms. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 27 and no more than 41 carbon atoms.
- the compound of Formula (II) is selected from any one of the following compounds: or a pharmaceutically acceptable salt of any of the foregoing.
- the compound of Formula (II) has formula: or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a compound selected from: or a pharmaceutically acceptable salt of any of the foregoing.
- a salt of a compound of this disclosure is formed between an acid and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group.
- the compound is a pharmaceutically acceptable acid addition salt.
- acids commonly employed to form pharmaceutically acceptable salts of the compounds of Formula (I) include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid, as well as organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, parabromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid, as well as related inorganic and organic acids.
- inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric
- Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne- 1,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylene sulfonate, phenylacetate, phenylpropionat
- bases commonly employed to form pharmaceutically acceptable salts of the compounds of Formula (I) include hydroxides of alkali metals, including sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, organic amines such as unsubstituted or hydroxyl-substituted mono-, di-, or tri- alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(Ci-C6)-alkylamine), such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D- glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such
- the compounds of Formula (I) or Formula (II), or pharmaceutically acceptable salts thereof are substantially isolated.
- the present disclosure provides a method of modulating interaction of a CD1 protein and a T cell, the method comprising contacting the CD1 protein with a compound as described herein, or a pharmaceutically acceptable salt thereof.
- the modulating comprises inhibiting or blocking.
- the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein, the method comprising contacting the CD1 protein on the surface of the cell with an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein on a surface of another cell, the method comprising contacting the CD1 protein on the surface of the cell with an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof.
- the cell is in the tissue selected from epithelial tissue, mucosal tissue, connective tissue, muscle tissue, skin tissue, fibrous tissue, vascular tissue, and nervous tissue.
- the cell is in the organ selected from lung, stomach, intestines, liver, thyroid, bladder, heart, eye, skin, kidney, gland, brain, pancreas, colon, lymph node, spleen, or prostate.
- the method include a cell in the skin.
- skin cells include any type of cell commonly found in skin, such as dendritic cells, B cells, macrophages, Langerhans cells, keratinocytes, melanocytes, Merkel cells, cells of the nerve endings, blood vessel cells, fibroblasts, adipocytes, mast cells, Schwann cells, or stem cells.
- the skin cell is a dendric cell.
- the skin cell is a Langerhans cell.
- the present disclosure provides a method of treating a disease, disorder, or condition responsive to inhibition of CD1 comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof.
- the CD1 protein is CD la, CD Id, or CD la and CD Id.
- the CD1 protein is CD la.
- the CD1 protein is CD Id.
- the CD1 protein is CD la and CD Id.
- the disease, disorder or condition is an inflammatory disease chosen from pruritus, nodular prurigo, itch, atopic dermatitis, eczema, psoriasis, common acne, acne vulgaris, urticaria, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, poison ivy (urushiol) dermatitis, Balsam of Peru dermatitis, contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions (cutaneous and systemic, including to sulfa antibiotics), Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen plan
- the contacting is carried out in vitro, in vivo, or ex vivo.
- the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein on a surface of a cell of a subject, the method comprising administering to the subject ( .g., in need thereof) a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof.
- the cell is in any of the organs or tissues of the subject as described herein.
- the cell is in the skin of the subject.
- the human CD1 protein is selected from CD la, CD lb. CDlc, and CD Id.
- the CD1 protein is CD la.
- the CD1 protein is CD lb.
- the CD1 protein is CDlc.
- the CD1 protein is CD Id.
- blocking the interaction of CD1 protein e.g., CD la protein
- a surface of a cell in a skin and a T cell results in treating inflammatory condition of the skin (e.g., dermatitis or psoriasis).
- the present disclosure provides a method of treating an inflammatory disease, the method comprising administering to a subject (e.g., in need thereof) a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same.
- a CD1 protein e.g., CD la, CD lb, CDlc, CD Id, or a combination of the foregoing
- the method comprises a step of identifying a subject in need of treatment for inflammatory disease or condition (e.g., inflammatory skin disease).
- the step of identifying may include (i) diagnosing the subject with the inflammatory disease or condition or (ii) identifying the subject diagnosed with the inflammatory disease or condition.
- the subject may be diagnosed with inflammatory disease or condition by a physician (e.g., treating physician) or diagnostician.
- the subject may be diagnosed on the basis of a physical examination, laboratory testing, imaging, or any combination of the foregoing.
- the subject may be diagnosed with an inflammatory disease on the basis of ex vivo blockade of T cells obtained from the organ or tissue of the subject (e.g., skin of the subject) by the lipid within the present claims.
- the subject may be diagnosed by testing for clinical response of the organ or tissue (e.g., skin) to the lipid treatment (e.g., “skin patch testing”).
- the inflammatory disease is selected from the group diabetes, rheumatoid arthritis, colitis, ulcerative colitis, asthma, allergic asthma, fatty liver disease, obesity, insulin resistance, inflammatory diseases of the liver and gut, steatohepatitis, liver inflammation, autoimmune diseases, atherosclerosis, hyperlipidemia, dyslipidemia, rhinitis, conjunctivitis, oral inflammation, thyroid disease, lung disease, inflammatory bowel disease (IBD), Crohn’s disease, and chronic obstructive airways disease.
- diabetes rheumatoid arthritis
- colitis ulcerative colitis
- asthma allergic asthma
- fatty liver disease obesity
- insulin resistance inflammatory diseases of the liver and gut
- steatohepatitis liver inflammation
- autoimmune diseases atherosclerosis
- hyperlipidemia dyslipidemia
- rhinitis conjunctivitis
- oral inflammation thyroid disease
- lung disease inflammatory bowel disease (IBD), Crohn’s disease
- IBD inflammatory bowel disease
- the inflammatory disease is inflammatory skin disease.
- the inflammatory skin disease is selected from atopic dermatitis, eczema, psoriasis, acne, acne vulgaris, urticaria, eczema, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, 1 contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen planus, erythema multiforme, urticaria, and other pruritic conditions,
- Examples of contact dermatitis include dermatitis from contact with skin creams, poison ivy, sulfa drugs, coenzyme Q, farnesol, balsam of Peru, or other contact allergens.
- Examples of inflammatory skin diseases also include skin inflammation caused by bacterial, fungal, or viral infections, or by an allergic reaction.
- the method of treating inflammatory skin condition includes administering the compound by applying a pharmaceutical formulation comprising the compound topically to the skin of the subject (e.g., as described herein).
- the disclosure provides a method of reducing T cell activation associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof.
- the disclosure provides a method of reducing expression of, activity of, and/or the release of a skin cytokine associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof.
- the skin cytokine is chosen from ILloc, IFN-y, IL-10, IL-6, IL17oc, IL-17f, TNFoc, and IL-22.
- the disclosure provides a method of reducing expression of, activity of, and/or the release of plasma cytokine associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof.
- the plasma cytokine is chosen from IFN-0, IL-4, and IL17oc.
- the inflammatory disease, disorder, or condition is responsive to inhibition of CD1.
- the inflammatory disease, disorder, or condition is associated with the skin.
- the present disclosure provides a method of ameliorating one or more symptoms associated with any one of the inflammatory skin diseases described herein. Suitable examples of these symptoms include rashes, itching, burning, redness of skin, swelling, blistering, scaling, pimples, and cracking or thickening of the inflamed area.
- compositions comprising, formulations, and routes of administration
- the present application also provides pharmaceutical compositions comprising an effective amount of a compound of the present disclosure (e.g., Formula (I) or Formula (II)) disclosed herein, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may also comprise any one of the additional therapeutic agents described herein.
- the application also provides pharmaceutical compositions and dosage forms comprising any one the additional therapeutic agents described herein.
- the carrier(s) are “acceptable” in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharmaceutically acceptable carrier, not deleterious to the recipient thereof in an amount used in the medicament.
- Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of the present application include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as ethanol, human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.
- ion exchangers alumina, aluminum stearate, lecithin
- serum proteins such as ethanol, human serum albumin
- compositions or dosage forms may contain any one of the compounds and therapeutic agents described herein in the range of 0.005% to 100% with the balance made up from the suitable pharmaceutically acceptable excipients.
- the contemplated compositions may contain 0.001%-100% of any one of the compounds and therapeutic agents provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%, wherein the balance may be made up of any pharmaceutically acceptable excipient described herein, or any combination of these excipients.
- compositions of the present application include those suitable for any acceptable route of administration.
- Acceptable routes of administration include, but are not limited to, buccal, cutaneous, subcutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intranasal, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal, nasogastric, ocular
- topical administration comprises administration to the skin.
- topical administration is administration to the skin.
- the topical compositions of the present disclosure can be prepared and used in the form of an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, oil, gel, hydrogel, lotion, mousse, ointment, powder, patch, pomade, solution, pump spray, stick, towelette, soap, or other forms commonly employed in the art of topical administration and/or cosmetic and skin care formulation.
- topical compositions can be in an emulsion form. Topical administration of the pharmaceutical compositions of the present application is especially useful when the desired treatment involves areas or organs readily accessible by topical application (e.g., skin).
- topical composition comprises a combination of any one of the compounds and therapeutic agents disclosed herein, and one or more additional ingredients, carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, anti-acne agents, preservatives, antioxidants, coloring agents/pigments, emollients (moisturizers), emulsifiers, film-forming/holding agents, fragrances, cosmetics, leave-on exfoliants, prescription drugs, preservatives, scrub agents, silicones, skin-identical/repairing agents, slip agents, sunscreen actives, surfactants/detergent cleansing agents, penetration enhancers, alcohol (including but not limited to ethanol) and thickeners.
- compositions and formulations described herein may conveniently be presented in a unit dosage form, e.g., tablets, sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier that constitutes one or more accessory ingredients.
- the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- compositions of the present application suitable for oral administration may be presented as discrete units such as capsules, sachets, granules or tablets each containing a predetermined amount (e.g., effective amount) of the active ingredient; a powder or granules; a solution or a suspension in an aqueous liquid or a non-aqueous liquid (such as ethanol); an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; packed in liposomes; or as a bolus, etc.
- Soft gelatin capsules can be useful for containing such suspensions, which may beneficially increase the rate of compound absorption.
- carriers that are commonly used include lactose, sucrose, glucose, mannitol, and silicic acid and starches.
- Other acceptable excipients may include: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol, ethanol, and glycerol monostearate, h) absorb
- useful diluents include lactose and dried corn starch.
- the active ingredient is combined with emulsifying and suspending agents.
- certain sweetening and/or flavoring and/or coloring agents may be added.
- Compositions suitable for oral administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.
- compositions suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions or infusion solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, saline (e.g., 0.9% saline solution) or 5% dextrose solution, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- the injection solutions may be in the form, for example, of a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- compositions of the present application may be administered in the form of suppositories for rectal administration.
- These compositions can be prepared by mixing a compound of the present application with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
- suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax, and polyethylene glycols.
- compositions of the present application may be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
- the present application provides an implantable drug release device impregnated with or containing a compound of this disclosure, or a composition comprising a compound of the present application and another therapeutic agent, such that said compound or therapeutic agent is released from said device and is therapeutically active.
- the compound can be administered in a skin-integrated or a skin-adhesive wearable device, including cloth patches or “patch tests.”
- a compound of the present disclosure e.g., a compound of Formula (I) or Formula (II) is present in an effective amount (e.g., a therapeutically effective amount).
- Effective doses may vary, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the subject, excipient usage, the possibility of co-usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician.
- an effective amount of the compound can range, for example, from about 0.001 mg/kg to about 500 mg/kg (e.g., from about 0.001 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 150 mg/kg; from about 0.01 mg/kg to about 100 mg/kg; from about 0.01 mg/kg to about 50 mg/kg; from about 0.01 mg/kg to about 10 mg/kg; from about 0.01 mg/kg to about 5 mg/kg; from about 0.01 mg/kg to about 1 mg/kg; from about 0.01 mg/kg to about 0.5 mg/kg; from about 0.01 mg/kg to about 0.1 mg/kg; from about 0.1 mg/kg to about 200 mg/kg; from about 0.1 mg/kg to about 150 mg/kg; from about 0.1 mg/kg to about 100 mg/kg; from about 0.1 mg/kg to about 50 mg/kg; from about
- an effective amount of the compound when administered topically (e.g., in ethanol solution, cream, or ointment), can range, for example, from about 0.001 mg per cm 2 of the skin (mg/cm 2 ) to about 50 mg/cm 2 (e.g., from about 0.01 mg/cm 2 to about 40 mg/cm 2 ; from about 0.1 mg/cm 2 to about 30 mg/cm 2 ; from about 0.5 mg/cm 2 to about 25 mg/cm 2 ; from about 1 mg/cm 2 to about 20 mg/cm 2 ; from about 1 mg/cm 2 to about 15 mg/cm 2 ; from about 1 mg/cm 2 to about 10 mg/cm 2 ; or from about 1 mg/cm 2 to about 5 mg/cm 2 ).
- an effective amount of a compound of Formula (I) or Formula (II) is about 0.5 mg/cm 2 , about 1 mg/cm 2 , about 2 mg/cm 2 , about 5 mg/cm 2 , or about 10 mg/cm 2 .
- the foregoing dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses, e.g., once daily, twice daily, thrice daily) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weekly, once every two weeks, once a month).
- the compound can be administered by applying a thin layer of a topical formulation (such as ethanol, cream or ointment) to the skin of the patient once a day or as needed, until the symptoms (e.g., rash or itch) are reduced or completely ameliorated.
- a topical formulation such as ethanol, cream or ointment
- kits useful for example, in the treatment of disorders, diseases and conditions referred to herein, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present disclosure.
- kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc.
- Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
- the kit may optionally include an additional therapeutic agent as described herein.
- the compounds of the present disclosure can be used in combination with at least one medication or therapy useful, e.g., in treating or alleviating symptoms of inflammatory skin disease.
- Suitable examples of such medications include corticosteroids, calcineurin inhibitors, or antibacterial or antifungal agents if the skin inflammation was caused by infection.
- the additional agent may be hydrocortisone, cortisone, prednisone, betamethasone, tixocortol, prednisolone, methylprednisolone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, beclometasone, dexamethasone, fluocortolone, halometasone, mometasone, clobetasol, halobetasol, diflorasone, or fluticasone, or a pharmaceutically acceptable salt thereof.
- the second agent may also be an NSAID (e.g., administered orally), such as ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, aspirin, or indomethacin, or a pharmaceutically acceptable salt thereof.
- NSAID e.g., administered orally
- the compound of the present disclosure may be administered to the patient simultaneously with the additional therapeutic agent (in the same pharmaceutical composition or dosage form or in different compositions or dosage forms) or consecutively (the additional therapeutic agent may be administered in a separate pharmaceutical composition or dosage form before or after administration of the compound of the present disclosure).
- the term “about” means “approximately” (e.g., plus or minus approximately 10% of the indicated value).
- substituents of compounds of the disclosure are disclosed in groups or in ranges. It is specifically intended that the disclosure include each and every individual subcombination of the members of such groups and ranges.
- the term “Ci-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, or Ce alkyl group in the alternative.
- the term “C1-6 alkyl” does not encompass a mixture of compounds with variable alkyl groups within the indicated range.
- Cn-m alkenyl refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons.
- alkyl refers to hydrocarbon group that may be straight- chain or branched, including isomethyl or anteisomethyl branched alkyls.
- the alkyl group may include one double carbon-carbon bond.
- the alkyl group may include two double carbon-carbon bonds (e.g., conjugated or unconjugated).
- n can be from 19 to 60, from 19 to 40, from 19 to 37, from 20 to 60, from 20 to 40, from 20 to 37, from 21 to 60, from 21 to 40, from 21 to 37, from 22 to 60, from 22 to 40, from 22 to 37, from 23 to 60, from 23 to 40, from 23 to 37, from 23 to 60, from 23 to 40, from 23 to 37, from 24 to 60, from 24 to 40, from 24 to 37, from 25 to 60, from 25 to 40, from 25 to 37, from 26 to 60, from 26 to 40, from 26 to 37, from 27 to 60, from 27 to 40, from 27 to 37, from 28 to 60, from 28 to 40, from 28 to 37, from 29 to 60, from 29 to 40, from 29 to 37, from 30 to 60, from 30 to 40, or from 30 to 37.
- m can be from 28 to 60, from 28 to 40, from 28 to 37, from 29 to 60, from 29 to 40, from 29 to 37, from 30 to 60, from 30 to 40, or from 30 to 37.
- alkyl length for any given formulation can vary as outlined above based on the CD1 isoform and tissue targeted, individual therapeutic doses will typically contain compounds with only one kind of optimized alkyl chain length.
- compound as used herein is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted, as well is isotopic variants, such as those including one or more isotopes at higher than natural abundance (e.g., deuterium and/or 13 C).
- Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.
- Known CD la ligands can have isomethyl or anteisomethyl branched alkane structures that promote CD la binding.
- the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated or synthesized as a mixture of isomers or as separated isomeric forms.
- the compound has the ⁇ -configuration. In some embodiments, the compound has the ( ⁇ -configuration.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H- imidazole, 1H-, 2H- and 4H- 1 ,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H- pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
- an in vitro cell can be a cell in a cell culture.
- an in vivo cell is a cell living in an organism such as a mammal.
- the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
- “contacting” the CD1 protein with a compound of the disclosure includes the administration of a compound of the present disclosure to an individual or patient, such as a human, having CD1 protein, as well as, for example, introducing a compound of the disclosure into a sample containing a cellular or purified preparation containing the CD1.
- the phrase “effective amount” or “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- treating refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
- preventing or “prevention” of a disease, condition or disorder refers to decreasing the risk of occurrence of the disease, condition or disorder in a subject or group of subjects (e.g., a subject or group of subjects predisposed to or susceptible to the disease, condition or disorder). In some embodiments, preventing a disease, condition or disorder refers to decreasing the possibility of acquiring the disease, condition or disorder and/or its associated symptoms. In some embodiments, preventing a disease, condition or disorder refers to completely or almost completely stopping the disease, condition or disorder from occurring.
- the exemplified compounds herein are synthetically engineered non-natural lipids that block T cell receptor binding and T cell inflammatory response.
- NMR spectra were recorded at 400 MHz or 300 MHz, using Bruker AV 400 and Bruker AV 300 spectrometers. Proton- decoupled 13 C NMR spectra were recorded at 100 MHz using a Bruker AV 400 spectrometer. Chemical shifts are reported as 5 values (ppm) referenced to the following solvent signals: CHCh, 5H 7.26; CDCh, 5c 77.0; CH3OH, 5H 3.34; CD3OD, 5c 49.9. When a 2: 1 mixture of CDCh and CD3OD was used as solvent, chemical shifts are reported referenced to the following solvent signals: CH3OH, 5H 3.34; CD3OD, 5c 49.9.
- Mass spectra were recorded on a liquid chromatography time-of-flight (LCT) spectrometer utilizing electrospray ionization with a methanol mobile phase and are reported as (m/z (%)).
- HRMS were recorded on a Micromass LCT spectrometer using a lock mass incorporated into the mobile phase. All reagents were obtained from commercial sources and were used without further purification, unless stated otherwise.
- Anhydrous solvents were purchased from Sigma- Aldrich, UK, and stored over 4 A molecular sieves and under an argon atmosphere.
- Analytical thin layer chromatography (TLC) was performed on aluminium plates pre-coated with Merck silica gel 60A F-254 as adsorbent.
- the developed plates were air-dried, visualized by UV detection (at 254 nm) and/or stained with 5% phosphomolybdic acid in EtOH (MPA spray).
- Compounds were purified by flash column chromatography on Merck silica gel (particle size 40-63 pm mesh) or Fluka 60 (40-60 pm mesh) silica gel.
- Step A General procedure for the C-alkylation of acetylide anions with ⁇ - bromocarboxylic acids to yield chain-extended carboxylic acids with internal alkyne group (-ynoic acids)
- n-Butyl lithium 2.5 M hexane solution, 2.5 mmol, 2.5 eq
- the reaction mixture was allowed to warm up to -20 °C over an hour.
- Step B General procedure for the hydrogenation of the internal alkyne in the -ynoic acid to yield internal cis-alkene in the -enoic acid.
- Step C General procedure for the synthesis of TV-hydroxysuccinimide (NHS) ester of the -enoic acids (Intermediates 11-20).
- Ethyl-3-(3-dimethylaminopropyl) carbodiimide (105 mg, 0.55 mmol, 1.1 eq), A-hydroxysuccinimide (70 mg, 0.60 mmol, 1.2 eq) and 4-dimethylaminopyridine (10% of acid weight) were added to a solution of the -enoic acid (0.50 mmol) in anhydrous DCM (10 mL). The resulting solution was heated at 40 °C for 4 h. Upon completion of the reaction, the solution was diluted with DCM (20 mL) and washed sequentially with H2O (20 mL) and brine (20 mL).
- C42:2 SM lipid allows the phosphocholine head group of the lipid to protrude broadly from CDla to block approaching T cell receptors (See FIGs 2 and 3).
- the second unsaturation in the fatty acyl unit is buried deep within the CDla pocket, where it serves to kink the acyl chain so that it curves to bind more efficiently within the pocket leading to higher potency action (FIG. 3, arrow pointing to unsaturation).
- sphingomyelins within mammalian cells occur as mixtures, and they are most commonly C34-C36 but can range up to C42 in length.
- the sphingomyelins preferentially eluted from CDla trended strongly towards the rare C42 sphingomyelins with two unsaturations, indicating that chain length >C36 and unsaturation > 1 can increase CDla binding efficiency.
- All compounds contain Cl 8: 1 sphingosine coupled to monounsaturated fatty acyl units ranging from C20 to C28, so that the overall combined length of the sphingosine and fatty acyl chains ranged from C38 to C46, so that they are longer than the most common natural sphingomyelins (C34-C36).
- the fatty acyl units were synthesized from defined precursors that allowed unsaturation to be placed at differing positions in the acyl chain from C9 (A9) to C17 (Al 7) (See Scheme 1). As the data showed, the position of double bond in the fatty acid affected CD la binding, since it is inserted inside the CD la cleft (FIG. 2).
- C46A17 SM efficacy of compound 10
- C46A17 SM efficacy of compound 10
- additional SM blockers include those with increased length of alkyl chains beyond C46, where the unsaturation is moved to more proximal positions in the fatty acyl chain and the number of unsaturations in the fatty acid chain is increased.
- the compounds contain terminal or near terminal alkane branches (isomethyls or anteisomethyls) in the fatty acyl chains.
- the natural cellular lipids are not suitable for use as T cell inhibitory drugs because they are present in trace amounts (nanograms) in cells, contain mixtures of short chain T cell agonists and long chain T cell antagonists, and do not represent the full spectrum of the kinds of synthetic lipids that would bind CD1 and T cell receptors.
- pure lipids synthesized with long chain length and headgroup distal unsaturations strongly blocked CDla binding to T cell receptors, as well as inflammation, and terminal methyl branching in fatty acids can influence lipid binding to CDla, so blockers can contain distal alkyl branching patterns.
- CD1 blocker compound is a synthetic lipid designated here as C46:2 Al 7 sphingomyelin (compound 10).
- compound 10 As the experimental data in this example shows, this compound strongly blocked CD la binding to human T cell receptors in vitro.
- compound 10 As shown in the following Example 2, formulated in ethanol and applied to human CD la expressing mice, compound 10 reduced skin swelling and cellular inflammation in vivo in a model of psoriasiform inflammation. Strong inflammation was seen only in CD la transgenic mice, and the structure-function analysis shows a correlation between CDla-T cell receptor blockade in vitro with human T cells and therapeutic response in the skin.
- the data support that the mechanism of action occurs specifically via CD la and T cell response, suggesting that unwanted side effects seen with steroids and other broadly acting T cell reagents might be lacking in CD la blocking lipids.
- Example 3 Formulation of sphingomyelin blockers for topical administration
- CD la is normally expressed on Langerhans cells in the epidermal layer of human skin. Because mice do not express CD la, the in vivo experiments were conducted with a human CD la knock-in mouse. CD la is non-polymorphic, and about 1 percent of human skin T cells stain with CD la tetramers suggesting the presence of large skin resident populations in vivo.
- the lipids of this disclosure block CD la binding to several T cell clones in vitro and also more broadly block the response of larger populations of polyclonal T cells that recognize CD la in vivo, leading to decreased inflammation in the skin.
- Synthetic long (C46:2 SMA17, compound 10), intermediate (C42:2A15 SM) and short chain (C34:l SM) sphingomyelins were compared for inflammatory response.
- these experiments used pure synthetic lipids to titrate CD la binding and inhibition of immune response.
- the functional requirements for the delivery vehicle are that it must: 1) dissolve amphipathic lipids, 2) be safe, immunologically unreactive, and non-toxic to skin and 3) create a lipid film that can subsequently penetrate to the epidermal layers, where CD la is normally located in human skin and in the skin of CD la transgenic mice.
- ethanol was chosen which is a chemically simple, safe and effective vehicle; however, other vehicles can also be used.
- C34:l SM which is not a T cell receptor blocker in tetramer assays, but serves a negative control for skin softening or other non-specific effects of sphingomyelin lipids, showed no statistically significant effects on ear thickening and fewer effects in the measurements of cellular and cytokine response.
- FIG. 8 Images of treated skin (Fig. 8) confirmed the patterns seen in ear thickness measurements and detection of cellular inflammation in the skin. Reduced inflammatory lesions were observed in skin treated with C42:2 SM and C46:2 SM as compared to short chain C34: 1 SM (FIG. 8) with the strongest effects seen with C46:2, which showed significantly reduced skin inflammation. High numbers of resident lymphocytes normally present in uninflammed skin so, as expected, treatments did not broadly reduce key resident cell populations, but there were some reductions in total T cell, neutrophil and eosinophil counts in ear skin and draining lymph node (FIG. 9A). Instead, the in vitro experimental data point to a likely reduction in T cell activation (rather than total numbers).
- CD la autoreactive A large fraction of human skin T cells are CD la autoreactive, and they are activated in psoriasis, atopic dermatitis and contact dermatitis. But there are currently no therapeutic approaches that directly target CD la binding lipid ligands.
- the present examples identify the molecules, molecular mechanisms and efficacy of non-natural synthetic CD la ligands in selective inhibition of CD la-dependent T cell responses in vitro in humans and in vivo in humanized mice.
- the compounds of the present examples represent a fundamentally new therapeutic approach based on selective inhibition of CD1- mediated T cell responses as distinguished from MHC-peptide and other T cell responses.
- the experimental data provide credible evidence that the compounds are useful to treat human diseases, e.g., in which CD la has been implicated, including 1) T cell responses to sebaceous oils (squalene) that are present in common acne and acne vulgaris lesions, 2) contact dermatitis from skin creams, balsam of Peru, farnesol, poison ivy, sulfa drugs, and other contact allergens, 3) psoriatic inflammation, 4) systemic type IV hypersensitivity responses to bee, wasp, and dust mite allergens and 5) chronic atopic dermatitis.
- These are all major diseases for which current therapy is suboptimal or for which current therapies generate unwanted, off-target effects based on their broader mechanisms of action.
- the 46:2 SM (compound 10) has been produced synthetically in milligram quantities, and the basic ethanol application system has been validated to show protection from disease in an in vivo mouse model.
- SM46:2 significantly reduced ear thickness and itching/pruritus scores below the vehicle control in the MC903-induced skin inflammatory response. Furthermore, an additional discovery was made that the SM46:2 significantly reduced ear thickness and pruritus below the wild-type mice treated with MC903 ( Figure 11).
- mice normally express CDld and then were engineered to express CD la.
- the suppression of response in wild type non-transgenic mice suggests that the SM46:2 has capacity to act as a dual blocker of hCDla and mCDld, and we have detected long chain sphingomyelins in association with CDld proteins in cells (Huang, Cell, 2023, in presss).
- CD la has not been previously linked with pruritus and so this represents a new area of biology and opens new areas for therapeutic application.
- Sulfatides (compounds S1-S1O) have the same kinds of CD la binding lipid tails as the synthetic sphingomyelins, but carry a differing headgroup comprised of sulfate and carbohydrate rather than phosphocholine.
- CD la was cocrystallized with sulfatide (FIG. 4), showing a molecular mechanism that can account for T cell blockade that is related to but somewhat different then the stearic interference mechanism for sphingomyelins (FIG. 3).
- CDla binding is mediated by alkyl chain interactions inside of the CDla cleft, suggesting that the length and saturation patterns observed for SMs with apply here.
- the head group of sulfatide has two proposed mechanisms for blocking TCR contact.
- Overlay of CD la- sulfatide shows that the large sulfate containing moiety occupied a similar space compared to the choline group of sphingomyelin, which is the blocking element for SM. This positioning suggests that the sulfo-sugar could sterically inhibit TCR approach in a manner analogous to the choline group in sphingomyelin (FIGs. 2 and 4, see Example 1).
- the sulfatide moiety also disrupts a triad of residues on the outer surface of CDla, which changes the intrinsic conformation of CDla at the site at which the TCR can bind.
- the sulfatide headgroup is chemically grafted onto the length and saturation optimized sphingolipid tails described in example 3.
- the following sulfatide compounds shown in Table SI can be prepared according to analogous methods and procedures shown for sphingomyelins in Scheme 2 above.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure provides lipid compounds useful in treating inflammatory skin diseases.
Description
MODULATORS OF CD1 PROTEIN BINDING TO T CELL RECEPTORS
CLAIM OF PRIORITY
This application claims priority U.S. Patent Application Serial No. 63/411,971, filed on September 30, 2022, the entire contents of which are hereby incorporated by reference.
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This disclosure was made with Government support under Grant No. AR048632 and AI049313 awarded by the National Institutes of Health. The Government has certain rights in the invention.
TECHNICAL FIELD
This disclosure relates to lipid compounds, and in particular to synthetic derivatives of sphingosine and unsaturated very long chain fatty acids (VLCFA) useful in treating inflammatory diseases, where CD1 proteins are implicated, such as inflammatory diseases of the skin.
BACKGROUND
Inflammatory skin diseases present a significant socioeconomic burden. Acne, contact dermatitis, atopic dermatitis, and psoriasis remain highly prevalent skin diseases that are only partially treated by current therapies, including those with non-specific effects on the immune system and skin, creating unwanted side effects. Spending on dermatitis and acne therapies exceeds 28 billion dollars per year worldwide and is constantly increasing. In a similar manner, psoriasis is a chronic, immune-mediated, inflammatory skin disease with a profound impact on patients’ quality of life. Psoriasis and acne may lead to social isolation, anxiety, distress and reduced self-esteem. Psoriasis patients experience a range of symptoms including itching and plaque-related pain. They are also at an increased risk of developing comorbidities, including depression, psoriatic arthritis, inflammatory bowel disease, metabolic disease, cardiovascular disease and diabetes. The impact of psoriasis and other inflammatory skin disease is not only limited
to those suffering from the disease, but also represents a significant burden on the health care system. Psoriasis, atopic dermatitis, and other inflammatory skin diseases lead to increased healthcare spending and limits employment opportunities and income of those affected by these conditions and their co-morbidities.
CD 1 -restricted T cells have been implicated in inflammatory conditions such as psoriasis, atopic dermatitis, and contact dermatitis. CD 1 -restricted T cells recognize lipid antigens and can be divided into 2 groups, group 1 CD1 (CD la, b, c)-restricted and group 2 CD Id-restricted T cells (NKT cells). Several findings have made them prime suspects in the pathogenesis of dermatological inflammatory conditions.
SUMMARY
In some embodiments, the present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein R1 is as described herein.
In some embodiments, the present disclosure provides a compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein R1 is as described herein.
In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is suitable for topical administration.
In some embodiments, the present disclosure provides a method of preventing or treating an inflammatory disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula
(II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same. In some embodiments, the inflammatory disease is an inflammatory skin disease.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present application belongs. Methods and materials are described herein for use in the present application; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
Other features and advantages of the present application will be apparent from the following detailed description and figures, and from the claims.
DESCRIPTION OF DRAWINGS
FIG. 1 contains a schematic showing T cell receptors binding peptide-MHC or lipid- CD1 complexes.
FIG. 2 contains a schematic showing natural lipids binding CD la and blocking T cell response.
FIG. 3 shows that the long chain doubly unsaturated sphingomyelin (42:2 SM) binds CD la with its phosphocholine headgroup protruding, which blocks approach of T cell receptors (42:2 SM). The more common short chain 36:2 SM binds by tucking its phosphocholine group largely inside CD la so T cell receptors can approach CD la and are not blocked.
FIG. 4 shows that sulfatide lipid compound with a green and yellow head group forms complex with CD la. Sulfatide sits similarly within CD la as compared to other lipids, but the sulfatide headgroup alters the protein surface of CD la and protrudes to the outer surface of CD la where it can block T cell receptors.
FIG. 5 shows inhibition of CD la binding to human T cells in vitro. Exemplified sphingomyelins block CDla protein binding to RCS36 T cells. Fluorescent human CDla tetramers were treated with media (mock) or a sphingomyelin variant synthesized with
the indicated fatty chain and tested for staining of human CD la autor eactive T cells using flow cytometry. In all cases the fatty acyl group is conjugated to a Cl 8: 1 sphingosine unit. Thus, the C28: 1 fatty acyl group and the Cl 8: 1 sphingosine group constitute C46:2 sphingomyelin (compound 10).
FIG. 6 shows sphingomyelin intervention model to modulate skin inflammation in vivo. Sphingomyelin species C34:l, C42:2 or C46:2 (20pg/20pl ethanol), or vehicle alone (20pl ethanol) were applied topically to WT or CD la transgenic mouse ear skin at 48 hour intervals before and during application of Aldara on days 0-5 (20 mg 5% imiquimod cream).
FIG. 7 shows that application of long chain sphingomyelins in vivo reduces imiquimod-induced skin thickening. Daily measurement of ear swelling induced by imiquimod treatment of wild-type (WT) and CD la transgenic mice (CD la) treated topically with 20pg sphingomyelin (SM34:1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6. (N=2-3, 2-way-ANOVA with Dunnett’s test, *, P < 0.05; ****, P < 0.0001 indicates significance on comparison to “CDla:EtOH” at day 7, mean ± SD).
FIG. 8 shows that application of very long chain sphingomyelins in vivo reduces imiquimod-induced skin inflammation. Representative images of imiquimod-treated wild-type (WT) and CD la transgenic mouse ear skin (CD la) treated topically with 20 pg sphingomyelin (SM34:1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6, images taken on day 7. Steroid is mometasone cream.
FIG. 9A shows the impact of sphingomyelin application on the imiquimod-induced cutaneous cellular immune response. Flow cytometry analysis of ear skin of imiquimod- treated wild-type (WT) and CD la transgenic mice (CD la) treated topically with 20 pg sphingomyelin (SM34:1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6. Skin T cell and draining lymph node T cell, frequency was determined. And lymph node CD4 and CD8 T cells assessed for cell surface CD69 expression, which is an indication of T cell activation. Skin and draining LN eosinophil and neutrophil frequency was determined. (N=2-3, 1-way-ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, mean ± SD).
FIG. 9B shows the impact of sphingomyelin application on the imiquimod-induced cutaneous cytokine-based immune response. Skin cytokine levels were assessed on day 7 of imiquimod-treated wild-type (WT) and CD la transgenic mice (CD la) treated topically with 20pg sphingomyelin (SM34: 1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6, as measured by cytometric bead array. (N=2-3, 1-way-ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, mean ± SD).
FIG. 10 shows the impact of sphingomyelin application on the imiquimod- induced systemic immune response. Plasma cytokine levels of the blood of imiquimod- treated wild-type (WT) and CD la transgenic mice (CD la) treated topically with 20 pg sphingomyelin (SM34:1, SM42:2 or SM46:2) dissolved in ethanol, or ethanol alone control, as in fig. 6, as measured by cytometric bead array. (N=2-3, 1-way-ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01, mean ± SD).
FIG. 11 show the impact of sphingomyelin application on MC903 type 2 inflammation and clinical itch. The ears of hCDla and WT mice were topically treated with Inmol MC903 /EtOH on days 0, 2 and 5. 20ug/20ul of SM 46:2, SM 42:2, SM 34: 1 and vehicle were applied on the ear tissue on days -2, 0, 2 and 4. (A) Ear thickness, and (B) itching frequency were evaluated at endpoint of day 6. Each data plot represents an individual ear. Plots show mean ± SEM. Statistics were calculated using one-way ANOVA with Tukey post-test. *** 0.01< P <0.001, ****p <0.001, NS = nonsignificant.
DETAILED DESCRIPTION
Without being bound by any particular theory, it is considered that CD1 proteins are expressed locally in defined tissues, such as the skin, where they bind lipids that activate human T cells to cause inflammation. The present disclosure is based, at least in part, on the realization that synthetic lipids such as those within the present claims bind CD1 but block activation of T cells, which effectively treats skin inflammation.
T cells recognize millions of antigens using rearranged and clonally distributed T cell receptors (TCRs). Activated T cells are the central effectors of many types of human immune response, as they orchestrate the actions of other T cells, B cells, dendritic cells and Natural Killer (NK) cells that are key causes of human autoimmune diseases. Many
studies of T cell mediated autoimmunity emphasize that TCRs control T cell activation, which occurs in response to peptide antigens presented by highly polymorphic Major Histocompatibility Complex (MHC) proteins (See FIG. 1, left). Because MHC genes are polymorphic, MHC antigen presenting proteins differ in their structure from person to person. Therefore, engineering of broadly activating or suppressive ligands of MHC proteins has not been broadly feasible for application in human populations. In contrast, the genes encoding human CD1 antigen presenting molecules are encoded outside the MHC, and functionally significant polymorphisms are extremely rare. Thus, CD1 proteins expressed by genetically unrelated individuals have similar or identical antigen binding clefts. Therefore, the simplified population genetics of the CD1 system offers an opportunity to take advantage of CD1 ligands discovered in human systems and then design individual lipid ligands that can be applied to affect T cells from nearly any human donor.
A second major feature of CD1 proteins is that they bind lipids (See FIG. 1, right), whereas MHC I and II bind and display peptides. As contrasted with the many peptide antigen agonists and antagonists of T cell responses that have been extensively investigated, lipid ligands of CD1 proteins have not been as broadly described and implemented as modulators of T cell function. In particular, the full scope of lipids from human cells bound by CD la, CD lb, CDlc and CD Id proteins has not been systematically reported. T cell antigen receptors provide strong, primary signals that control the activation, de-activation or death of T cells. Without being bound by any particular theory or speculation, it is considered that the lipidic compounds within the present claims modulate T cell autoimmunity by modulating T cell receptor contact with non-polymorphic CD1 proteins. Engineering lipid ligands that efficiently bind CD1 proteins and broadly block TCR binding and activation could selectively inhibit CD1- reactive T cells without substantially changing other aspects of the immune system.
The four types of human CD1 antigen presenting proteins, CD la, CD lb, CDlc and CD Id, are expressed at high density on dendritic cells, macrophages, and B cells, which are the major antigen presenting cells in the human body. CD1 proteins bind many types of lipids to form complexes that engage T cell receptors (e.g., aPTCRs or ySTCRs) leading to T cell activation. CD la, CD lb, CDlc and CD Id proteins each have a distinct
lipid binding clefts that accommodate differing patterns of lipid ligands. Newly synthesized CD1 proteins fold in the endoplasmic reticulum, where they capture lipids and traffic as CD 1 -lipid complexes through the secretory pathway to the cell surface. A cohort of CD1 proteins on a given cell bind diverse lipids, which generates CD1 lipid complexes that either do or do not bind to the major activating receptors on T cells known as o.p T cell receptors or y5 T cell receptors. CD1 proteins can capture self or foreign lipids for display to T cells.
In the most studied examples, CD1 ligands use their aliphatic hydrocarbon tails, also known as lipid anchors, to bind within a hydrophobic cleft in CD1. This mode of binding allows the carbohydrate, sulfate, choline or other hydrophilic head groups to protrude to the surface of CD1 (See FIG. 1). The TCR can recognize an epitope that is formed by the surface of CD1 itself (i.e., CD1 autoreactive T cells) or by a combination of the CD1 protein and the protruding head group of each lipid antigen (lipid reactive T cell). Most previously studied lipid ligands of CD1 were discovered in activation assays and have activating properties for T cells. Without being bound to any particular theory, the CD1 ligands described in this application were discovered through binding assays. Therefore, the ligands reported have particularly strong CD1 binding properties, but can lead to activation, no effect, or blockade of functional T cell responses.
The compounds and methods of this disclosure advantageously block the binding and interaction between CD1 and lipid-reactive TCRs, thereby blocking the activation response of TCRs that directly bind to outer surface of CD1 proteins in the absence of any lipid antigen (See Figure 2). In particular, the chemical design and synthetic production of antigens with longer and unsaturated alkyl chains allows stronger binding of synthetic analogs to CD1 proteins. Also, the longer alkyl chains position the hydrophilic head groups so that they protrude more extensively from the surface of CD1, which allows dominant negative inhibition of CD1 to many types TCRs that might otherwise bind to CD1.
The four types of CD1 proteins, CD la, CD lb, CDlc and CD Id, are expressed on the major antigen presenting cell types found throughout the human body, including dendritic cells, B cells, macrophages and thymocytes. All four types of human CD1 proteins activate both a and y5 T cells from the blood, demonstrating systemic immune
responses. Further, through study of human T cells, CD Id knockout mice or human CD la transgenic mice, there is clear and credible evidence for CD 1 -mediated T cell response to viral, fungal and bacterial infections, as well as models of autoimmune diseases, anticancer response and T cell mediated drug interactions. Therefore, by measuring the molecular size, chemical structure, lipid length, and lipid saturation present in ligands isolated from each of the four human CD1 antigen presenting molecule types, data in this disclosure allows for discovery and synthetic optimization of ligands that bind to CD la, CD lb, CDlc and CD Id, and by modulating the size of the lipid anchor or head group, synthetic compounds effectively blocking interaction of the CD1 isoform and a T cell can be prepared.
However, each type of CD1 protein has a distinctly shaped ligand binding groove. Each CD1 protein type shows distinct patterns of expression in the human body. For example, skin shows highest expression of CD la, whereas gut and liver show highest expression of CD Id. All four human CD1 isoforms activate human T cells that circulate in the blood. The current examples discussed in this proposal emphasize one case in which CD la is expressed at high levels in skin, and CD la ligands are applied topically in skin. However, CD lb, CDlc and CD Id can also be expressed in human skin, and CD la is expressed in other organs in the body. Thus, lipid ligands that bind any of the four types of human CD1 antigen presenting molecules (CD la, CD lb, CDlc, CD Id) can be developed as immune regulators and applied using enteral, parenteral, topical, intradermal, mucosal or other routes.
T cell autoreactivity toward human CD1 proteins is known for human CD la, CD lb, CDlc, and CD Id. The frequency of CD la autoreactive T cells in the blood and skin is particularly high, when measured using limiting dilution cloning, single cell ELISA or tetramer assays. Lipid-loaded CD1 tetramers are oligomerized antigen presenting molecules that directly detect binding of TCRs to measure the rate of T cell response to any defined antigen or antigen presenting molecule. In skin, CD la tetramerbinding T cells are about 100-fold more frequent than CD lb tetramer-binding T cells, and CD la autoreactive tetramer+ T cells account for approximately 1 % of total T cells on average and range to more than 20 percent in selected donors. Likewise, CD la proteins are expressed at high density in skin, where they are found on myeloid dendritic cells and
at particularly high density on Langerhans cells (LCs). Also, self-antigens for CD la are extracted from skin in larger amounts than from other tissues.
The abundance of CD la autoreactive T cells, CD la protein and CD la- presented antigens raises basic questions about possible mechanisms of inhibition of CD la autoreactivity, which might otherwise result in autoimmune disease (See FIG. 2). Indeed, recent studies show that CD la autoreactive T cells are present at higher levels in human skin involved with atopic dermatitis and psoriasis, as compared to skin from healthy donors or non-involved skin. Also, common allergens such as house dust mites contain phospholipase activity and generate lysolipids that bind to CD la and contribute to T- intradermal cell response. In addition, squalene, which is a common lipid whose overproduction in acne syndromes (common acne, acne vulgaris), has been identified as a CD la presented autoantigen. Further, transgenic expression of human CD la in mouse skin results in marked augmentation of immune response to the contact dermatitis antigen, urushiol (poison ivy) as well as the TLR agonist imiquimod, which is widely used as a model of psoriasiform and dermatitic skin inflammation.
Against this background in which CD la and skin lipids cause T cell mediated inflammation in the skin, the present disclosure provides compounds that specifically block interaction of a CD la protein and T cell receptors, which in turn blocks CD la- mediated T cell response or inflammation both in vitro and in vivo. Pharmaceutical compositions including these compounds (e.g., for topical application to skin) and methods of using these compounds and compositions, e.g., for treating skin inflammatory diseases are also provided. The compositions of matter and synthetic approaches for molecules described in this disclosure generate compounds that are both more homogenous and chemically different from the structures of endogenous lipids normally present in skin. The chemical structures present in novel synthetic sphingomyelins or sulfatides, which distinguish them from their natural counterparts in skin, account for optimal T cell inhibition. These proven approaches can be applied to other CD1 isoforms that bind distinct lipids and are expressed outside the skin.
Compounds of Formula (I)
In some embodiments, the present application provides a compound of Formula
In some embodiments, R1 is C19-37 alkenyl. In some embodiments, R1 is C20-41 alkenyl. In some embodiments, R1 is C21-37 alkenyl. In some embodiments, R1 is C22-41 alkenyl. In some embodiments, R1 is C23-37 alkenyl. In some embodiments, R1 is C24-41 alkenyl. In some embodiments, R1 is C25-37 alkenyl. In some embodiments, R1 is C26-41 alkenyl. In some embodiments, R1 is C27-37 alkenyl. In some embodiments, R1 is C28-41 alkenyl. In some embodiments, R1 is C29-37 alkenyl. In some embodiments, R1 is C30-41 alkenyl. In some embodiments, R1 is C31-37 alkenyl. In some embodiments, R1 is C32-41 alkenyl. In some embodiments, R1 is C27 alkenyl. In some embodiments, R1 is C28 alkenyl. In some embodiments, R1 is C29 alkenyl. In some embodiments, R1 is C30 alkenyl. In some embodiments, R1 is C31 alkenyl. In some embodiments, R1 is C32 alkenyl. In some embodiments, R1 is C33 alkenyl. In some embodiments, R1 is C34 alkenyl. In some embodiments, R1 is C35 alkenyl. In some embodiments, R1 is C36 alkenyl. In some embodiments, R1 is C37 alkenyl. In some embodiments, R1 is C38 alkenyl. In some embodiments, R1 is C40 alkenyl.
In some embodiments, any of said alkenyl groups comprises 2 double bonds. In some embodiments, the 2 double bonds are conjugated. In some embodiments, the 2 double bonds are not conjugated. In some embodiments, any of said alkenyl groups comprises 1 double bond.
In some embodiments, any of the double bonds is at C9, Cll, C13, C15, C17, or Cl 9 in the alkenyl group of R1. In some embodiments, the double bond is at C9. In some embodiments, the double bond is at Cll. In some embodiments, the double bond is at Cl 3. In some embodiments, the double bond is at Cl 5. In some embodiments, the double bond is at Cl 7. In some embodiments, the double bond is at Cl 9.
In some embodiments, any of the double bonds is Z configuration. In some embodiments, any of the double bonds is E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R1 comprises 2 double bonds each in Z configuration. In some embodiments, the alkenyl group of R1 comprises 2 double bonds each in E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in E configuration and 1 double bond in Z configuration.
In some embodiments, the compound of Formula (I) has formula:
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula (I) has formula:
or a pharmaceutically acceptable salt thereof, wherein x and y are as described herein. In some embodiments, x is an integer from 3 to 13 and y is an integer from 6 to 26. In some embodiments, x is an integer from 3 to 13 and y is an integer from 16 to 26. In some embodiments, x is an integer from 3 to 13 and y is an integer from 6 to 16. In some embodiments, x is an integer from 3 to 13 and y is an integer from 8 to 16. In some embodiments, x is 3, 5, 7, 9, or 11. In some embodiments, x is 3. In some embodiments, x is 5. In some embodiments, x is 7. In some embodiments, x is 9. In some embodiments, x is 11. In some embodiments, y is from 0 to 26. In some embodiments, y is 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26. In some embodiments, x is 3, and y is from 8 to 26. In some embodiments, x is 3 and y is from 16 to 26. In some embodiments, x is 5, and y is from 6 to 24. In some embodiments, x is 5 and y is from 14 to 24. In some
embodiments, x is 7, and y is from 4 to 22. In some embodiments, x is 5 and y is from 12 to 22. In some embodiments, x is 9, and y is from 2 to 20. In some embodiments, x is 5 and y is from 10 to 20. In some embodiments, x is 11, and y is from 2 to 20. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 19 and no more than 41 carbon atoms. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 27 and no more than 41 carbon atoms.
In some embodiments, the compounds or Formula (I) are selected from any one of the following compounds in Table 1.
(42:2 SMA15 (24:1 Al 5)) or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula (I) has formula:
or a pharmaceutically acceptable salt thereof.
Compounds of Formula (II)
In some embodiments, the present application provides a compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein R1 is as described herein.
In some embodiments, R1 is C19-37 alkenyl. In some embodiments, R1 is C20-41 alkenyl. In some embodiments, R1 is C21-37 alkenyl. In some embodiments, R1 is C22-41 alkenyl. In some embodiments, R1 is C23-37 alkenyl. In some embodiments, R1 is C24-41 alkenyl. In some embodiments, R1 is C25-37 alkenyl. In some embodiments, R1 is C26-41 alkenyl. In some embodiments, R1 is C27-37 alkenyl. In some embodiments, R1 is C28-41 alkenyl. In some embodiments, R1 is C29-37 alkenyl. In some embodiments, R1 is C30-41 alkenyl. In some embodiments, R1 is C31-37 alkenyl. In some embodiments, R1 is C32-41 alkenyl. In some embodiments, R1 is C27 alkenyl. In some embodiments, R1 is C28 alkenyl. In some embodiments, R1 is C29 alkenyl. In some embodiments, R1 is C30 alkenyl. In some embodiments, R1 is C31 alkenyl. In some embodiments, R1 is C32 alkenyl. In some embodiments, R1 is C33 alkenyl. In some embodiments, R1 is C34 alkenyl. In some embodiments, R1 is C35 alkenyl. In some embodiments, R1 is C36 alkenyl. In some embodiments, R1 is C37 alkenyl. In some embodiments, R1 is C38 alkenyl. In some embodiments, R1 is C40 alkenyl.In some embodiments, R1 is C19 alkenyl. In some embodiments, R1 is C20 alkenyl. In some embodiments, R1 is C21 alkenyl.
In some embodiments, R1 is C22 alkenyl. In some embodiments, R1 is C23 alkenyl. In some embodiments, R1 is C24 alkenyl. In some embodiments, R1 is C25 alkenyl. In some embodiments, R1 is C26 alkenyl. In some embodiments, R1 is C27 alkenyl. In some embodiments, R1 is C28 alkenyl. In some embodiments, R1 is C29 alkenyl. In some embodiments, R1 is C30 alkenyl. In some embodiments, R1 is C31 alkenyl. In some embodiments, R1 is C32 alkenyl. In some embodiments, R1 is C33 alkenyl. In some embodiments, R1 is C34 alkenyl. In some embodiments, R1 is C35 alkenyl. In some embodiments, R1 is C36 alkenyl. In some embodiments, R1 is C38 alkenyl. In some embodiments, R1 is C40 alkenyl.
In some embodiments, any of said alkenyl groups comprises 2 double bonds. In some embodiments, the 2 double bonds are conjugated. In some embodiments, the 2 double bonds are not conjugated. In some embodiments, any of said alkenyl groups comprises 1 double bond.
In some embodiments, any of the double bonds is at C9, Cll, C13, C15, C17, or Cl 9 in the alkenyl group of R1. In some embodiments, the double bond is at C9. In some embodiments, the double bond is at Cll. In some embodiments, the double bond is at Cl 3. In some embodiments, the double bond is at Cl 5. In some embodiments, the double bond is at Cl 7. In some embodiments, the double bond is at Cl 9.
In some embodiments, the alkenyl group of R1 has one double bond at C9, Cll, C13, C15, C17, or C19. In some embodiments, the alkenyl group of R1 has double bonds at two of C9, Cll, C13, C15, C17, and C19.
In some embodiments, any of the double bonds is Z configuration. In some embodiments, any of the double bonds is E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in Z configuration. In some embodiments, the alkenyl group of R1 comprises 2 double bonds each in Z configuration. In some embodiments, the alkenyl group of R1 comprises 2 double bonds each in E configuration. In some embodiments, the alkenyl group of R1 comprises 1 double bond in E configuration and 1 double bond in Z configuration.
In some embodiments, the compound of Formula (II) has formula:
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula (II) has formula:
or a pharmaceutically acceptable salt thereof, wherein x and y are as described herein. In some embodiments, x is an integer from 3 to 13 and y is an integer from 6 to 26. In some embodiments, x is an integer from 3 to 13 and y is an integer from 16 to 26. In some embodiments, x is an integer from 3 to 13 and y is an integer from 6 to 16. In some embodiments, x is an integer from 3 to 13 and y is an integer from 8 to 16. In some embodiments, x is 3, 5, 7, 9, or 11. In some embodiments, x is 3. In some embodiments, x is 5. In some embodiments, x is 7. In some embodiments, x is 9. In some embodiments, x is 11. In some embodiments, y is from 0 to 26. In some embodiments, y is 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26. In some embodiments, x is 3, and y is from 8 to 26. In some embodiments, x is 3 and y is from 16 to 26. In some embodiments, x is 5, and y is from 6 to 24. In some embodiments, x is 5 and y is from 14 to 24. In some embodiments, x is 7, and y is from 4 to 22. In some embodiments, x is 5 and y is from 12 to 22. In some embodiments, x is 9, and y is from 2 to 20. In some embodiments, x is 5 and y is from 10 to 20. In some embodiments, x is 11, and y is from 2 to 20. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 19 and no more than 41 carbon atoms. In some embodiments, the hydrocarbon chain comprising x and y comprises at least 27 and no more than 41 carbon atoms.
In some embodiments, the compound of Formula (II) is selected from any one of the following compounds:
or a pharmaceutically acceptable salt of any of the foregoing.
In some embodiments, the compound of Formula (II) has formula:
or a pharmaceutically acceptable salt thereof.
In some embodiments, the present disclosure provides a compound selected from:
or a pharmaceutically acceptable salt of any of the foregoing.
Pharmaceutically acceptable salts
In some embodiments, a salt of a compound of this disclosure is formed between an acid and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group. According to another embodiment, the compound is a pharmaceutically acceptable acid addition salt.
In some embodiments, acids commonly employed to form pharmaceutically acceptable salts of the compounds of Formula (I) include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid, as well as organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, parabromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid, as well as related inorganic and organic acids. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne- 1,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylene sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, P-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene- 1 -sulfonate, naphthal ene-2- sulfonate, mandelate and other salts. In one embodiment, pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and especially those formed with organic acids such as maleic acid.
In some embodiments, bases commonly employed to form pharmaceutically acceptable salts of the compounds of Formula (I) include hydroxides of alkali metals, including sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, organic amines such as unsubstituted or hydroxyl-substituted mono-, di-, or tri-
alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(Ci-C6)-alkylamine), such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D- glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, and the like.
In some embodiments, the compounds of Formula (I) or Formula (II), or pharmaceutically acceptable salts thereof, are substantially isolated.
Methods of use
In one general aspect, the present disclosure provides a method of modulating interaction of a CD1 protein and a T cell, the method comprising contacting the CD1 protein with a compound as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the modulating comprises inhibiting or blocking.
In some embodiments, the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein, the method comprising contacting the CD1 protein on the surface of the cell with an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein on a surface of another cell, the method comprising contacting the CD1 protein on the surface of the cell with an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cell is in the tissue selected from epithelial tissue, mucosal tissue, connective tissue, muscle tissue, skin tissue, fibrous tissue, vascular tissue, and nervous tissue. In some embodiments, the cell is in the organ selected from lung, stomach, intestines, liver, thyroid, bladder, heart, eye, skin, kidney, gland, brain, pancreas, colon, lymph node, spleen, or prostate. In some embodiments, the method include a cell in the skin. Suitable examples of skin cells include any type of cell commonly found in skin, such as dendritic cells, B cells, macrophages, Langerhans cells, keratinocytes, melanocytes, Merkel cells, cells of the nerve endings, blood vessel cells, fibroblasts, adipocytes, mast cells, Schwann cells, or stem cells. In some embodiments, the skin cell is a dendric cell. In some embodiments, the skin cell is a Langerhans cell.
In some embodiments, the present disclosure provides a method of treating a disease, disorder, or condition responsive to inhibition of CD1 comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the CD1 protein is CD la, CD Id, or CD la and CD Id. In some embodiments, the CD1 protein is CD la. In some embodiments, the CD1 protein is CD Id. In some embodiments, the CD1 protein is CD la and CD Id.
In some embodiments, the disease, disorder or condition is an inflammatory disease chosen from pruritus, nodular prurigo, itch, atopic dermatitis, eczema, psoriasis, common acne, acne vulgaris, urticaria, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, poison ivy (urushiol) dermatitis, Balsam of Peru dermatitis, contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions (cutaneous and systemic, including to sulfa antibiotics), Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen planus, erythema multiforme, urticaria, other pruritic conditions, and other allergic and irritant skin diseases. In some embodiments, the contacting is carried out in vitro, in vivo, or ex vivo. In some embodiments, the present disclosure provides a method of inhibiting interaction of a T cell and a CD1 protein on a surface of a cell of a subject, the method comprising administering to the subject ( .g., in need thereof) a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cell is in any of the organs or tissues of the subject as described herein. In some embodiments, the cell is in the skin of the subject.
In some embodiments, the human CD1 protein is selected from CD la, CD lb. CDlc, and CD Id. In some embodiments, the CD1 protein is CD la. In some embodiments, the CD1 protein is CD lb. In some embodiments, the CD1 protein is CDlc. In some embodiments, the CD1 protein is CD Id. Without being bound by any particular theory or speculation, blocking the interaction of CD1 protein (e.g., CD la protein) on a surface of a cell and a T cell results in treating inflammatory condition of the organ or tissue where the cell is located. In some embodiments, blocking the interaction of CD1
protein (e.g., CD la protein) on a surface of a cell in a skin and a T cell results in treating inflammatory condition of the skin (e.g., dermatitis or psoriasis).
Accordingly, in some embodiments, the present disclosure provides a method of treating an inflammatory disease, the method comprising administering to a subject (e.g., in need thereof) a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same. In some embodiments, a CD1 protein (e.g., CD la, CD lb, CDlc, CD Id, or a combination of the foregoing) is implicated in the pathology of the inflammatory disease. In some embodiments, the method comprises a step of identifying a subject in need of treatment for inflammatory disease or condition (e.g., inflammatory skin disease). For example, the step of identifying may include (i) diagnosing the subject with the inflammatory disease or condition or (ii) identifying the subject diagnosed with the inflammatory disease or condition. The subject may be diagnosed with inflammatory disease or condition by a physician (e.g., treating physician) or diagnostician. The subject may be diagnosed on the basis of a physical examination, laboratory testing, imaging, or any combination of the foregoing. For example, the subject may be diagnosed with an inflammatory disease on the basis of ex vivo blockade of T cells obtained from the organ or tissue of the subject (e.g., skin of the subject) by the lipid within the present claims. In another example, the subject may be diagnosed by testing for clinical response of the organ or tissue (e.g., skin) to the lipid treatment (e.g., “skin patch testing”).
In some embodiments, the inflammatory disease (e.g., in which CD1 is implicated in pathology) is selected from the group diabetes, rheumatoid arthritis, colitis, ulcerative colitis, asthma, allergic asthma, fatty liver disease, obesity, insulin resistance, inflammatory diseases of the liver and gut, steatohepatitis, liver inflammation, autoimmune diseases, atherosclerosis, hyperlipidemia, dyslipidemia, rhinitis, conjunctivitis, oral inflammation, thyroid disease, lung disease, inflammatory bowel disease (IBD), Crohn’s disease, and chronic obstructive airways disease.
In some embodiments, the inflammatory disease (e.g., in which CD1 is implicated in pathology) is inflammatory skin disease. In some embodiments, the inflammatory skin disease is selected from atopic dermatitis, eczema, psoriasis, acne, acne vulgaris, urticaria, eczema, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, 1
contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen planus, erythema multiforme, urticaria, and other pruritic conditions, and other allergic and irritant skin diseases. Examples of contact dermatitis include dermatitis from contact with skin creams, poison ivy, sulfa drugs, coenzyme Q, farnesol, balsam of Peru, or other contact allergens. Examples of inflammatory skin diseases also include skin inflammation caused by bacterial, fungal, or viral infections, or by an allergic reaction.
In some embodiments, the method of treating inflammatory skin condition includes administering the compound by applying a pharmaceutical formulation comprising the compound topically to the skin of the subject (e.g., as described herein).
In some embodiments, the disclosure provides a method of reducing T cell activation associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof.
In some embodiments, the disclosure provides a method of reducing expression of, activity of, and/or the release of a skin cytokine associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the skin cytokine is chosen from ILloc, IFN-y, IL-10, IL-6, IL17oc, IL-17f, TNFoc, and IL-22. In some embodiments, the disclosure provides a method of reducing expression of, activity of, and/or the release of plasma cytokine associated with an inflammatory disease, disorder, or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the plasma cytokine is chosen from IFN-0, IL-4, and IL17oc. In some embodiments, the inflammatory disease, disorder, or condition is responsive to inhibition of CD1. In some embodiments, the inflammatory disease, disorder, or condition is associated with the skin. In some embodiments, the present disclosure provides a method of ameliorating one or more symptoms associated with any
one of the inflammatory skin diseases described herein. Suitable examples of these symptoms include rashes, itching, burning, redness of skin, swelling, blistering, scaling, pimples, and cracking or thickening of the inflamed area.
Compositions, formulations, and routes of administration
The present application also provides pharmaceutical compositions comprising an effective amount of a compound of the present disclosure (e.g., Formula (I) or Formula (II)) disclosed herein, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The pharmaceutical composition may also comprise any one of the additional therapeutic agents described herein. In certain embodiments, the application also provides pharmaceutical compositions and dosage forms comprising any one the additional therapeutic agents described herein. The carrier(s) are “acceptable” in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharmaceutically acceptable carrier, not deleterious to the recipient thereof in an amount used in the medicament.
Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of the present application include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as ethanol, human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.
The compositions or dosage forms may contain any one of the compounds and therapeutic agents described herein in the range of 0.005% to 100% with the balance made up from the suitable pharmaceutically acceptable excipients. The contemplated compositions may contain 0.001%-100% of any one of the compounds and therapeutic agents provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%, wherein the balance may be made up of any
pharmaceutically acceptable excipient described herein, or any combination of these excipients.
Routes of administration and dosage forms
The pharmaceutical compositions of the present application include those suitable for any acceptable route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, subcutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intranasal, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal, nasogastric, ocular, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral and vaginal.
In some embodiments, the compounds described herein (e.g., compounds of Formula (I), Formula (II), or a pharmaceutically acceptable salt of any of the foregoing) can be administered topically, e.g., in a topical dosage form. In some embodiments, topical administration comprises administration to the skin. In some embodiments, topical administration is administration to the skin. The topical compositions of the present disclosure can be prepared and used in the form of an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, oil, gel, hydrogel, lotion, mousse, ointment, powder, patch, pomade, solution, pump spray, stick, towelette, soap, or other forms commonly employed in the art of topical administration and/or cosmetic and skin care formulation. The topical compositions can be in an emulsion form. Topical administration of the pharmaceutical compositions of the present application is especially useful when the desired treatment involves areas or organs readily accessible by topical application (e.g., skin). In some embodiments, the topical composition comprises a combination of any one of the compounds and therapeutic agents disclosed herein, and one or more additional ingredients, carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, anti-acne agents, preservatives, antioxidants, coloring
agents/pigments, emollients (moisturizers), emulsifiers, film-forming/holding agents, fragrances, cosmetics, leave-on exfoliants, prescription drugs, preservatives, scrub agents, silicones, skin-identical/repairing agents, slip agents, sunscreen actives, surfactants/detergent cleansing agents, penetration enhancers, alcohol (including but not limited to ethanol) and thickeners.
Compositions and formulations described herein may conveniently be presented in a unit dosage form, e.g., tablets, sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.
In some embodiments, any one of the compounds and therapeutic agents disclosed herein are administered orally. Compositions of the present application suitable for oral administration may be presented as discrete units such as capsules, sachets, granules or tablets each containing a predetermined amount (e.g., effective amount) of the active ingredient; a powder or granules; a solution or a suspension in an aqueous liquid or a non-aqueous liquid (such as ethanol); an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; packed in liposomes; or as a bolus, etc. Soft gelatin capsules can be useful for containing such suspensions, which may beneficially increase the rate of compound absorption. In the case of tablets for oral use, carriers that are commonly used include lactose, sucrose, glucose, mannitol, and silicic acid and starches. Other acceptable excipients may include: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol, ethanol, and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium
stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. Compositions suitable for oral administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.
Compositions suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions or infusion solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, saline (e.g., 0.9% saline solution) or 5% dextrose solution, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets. The injection solutions may be in the form, for example, of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
The pharmaceutical compositions of the present application may be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of the present application with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will
melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycols.
The pharmaceutical compositions of the present application may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
According to another embodiment, the present application provides an implantable drug release device impregnated with or containing a compound of this disclosure, or a composition comprising a compound of the present application and another therapeutic agent, such that said compound or therapeutic agent is released from said device and is therapeutically active. For example, the compound can be administered in a skin-integrated or a skin-adhesive wearable device, including cloth patches or “patch tests.”
Dosages and regimens
In the pharmaceutical compositions of the present application, a compound of the present disclosure (e.g., a compound of Formula (I) or Formula (II)) is present in an effective amount (e.g., a therapeutically effective amount). Effective doses may vary, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the subject, excipient usage, the possibility of co-usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician.
In some embodiments, an effective amount of the compound (e.g., Formula (I) or Formula (II)) can range, for example, from about 0.001 mg/kg to about 500 mg/kg (e.g., from about 0.001 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 150 mg/kg; from about 0.01 mg/kg to about 100 mg/kg; from about 0.01 mg/kg to about 50 mg/kg; from about 0.01 mg/kg to about 10 mg/kg; from about 0.01 mg/kg to about 5 mg/kg; from about 0.01 mg/kg to about 1 mg/kg; from about 0.01 mg/kg to about 0.5 mg/kg; from about 0.01 mg/kg to about 0.1 mg/kg; from about 0.1 mg/kg to about 200 mg/kg; from about 0.1 mg/kg to about 150 mg/kg; from
about 0.1 mg/kg to about 100 mg/kg; from about 0.1 mg/kg to about 50 mg/kg; from about 0.1 mg/kg to about 10 mg/kg; from about 0.1 mg/kg to about 5 mg/kg; from about 0.1 mg/kg to about 2 mg/kg; from about 0.1 mg/kg to about 1 mg/kg; or from about 0.1 mg/kg to about 0.5 mg/kg). In some embodiments, an effective amount of a compound of Formula (I) or Formula (II) is about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, or about 5 mg/kg.
In some embodiments, when administered topically (e.g., in ethanol solution, cream, or ointment), an effective amount of the compound (e.g., Formula (I) or Formula (II)) can range, for example, from about 0.001 mg per cm2 of the skin (mg/cm2) to about 50 mg/cm2 (e.g., from about 0.01 mg/cm2 to about 40 mg/cm2; from about 0.1 mg/cm2 to about 30 mg/cm2; from about 0.5 mg/cm2 to about 25 mg/cm2; from about 1 mg/cm2 to about 20 mg/cm2; from about 1 mg/cm2 to about 15 mg/cm2; from about 1 mg/cm2 to about 10 mg/cm2; or from about 1 mg/cm2 to about 5 mg/cm2). In some embodiments, an effective amount of a compound of Formula (I) or Formula (II) is about 0.5 mg/cm2, about 1 mg/cm2, about 2 mg/cm2, about 5 mg/cm2, or about 10 mg/cm2.
The foregoing dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses, e.g., once daily, twice daily, thrice daily) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weekly, once every two weeks, once a month). For example, the compound can be administered by applying a thin layer of a topical formulation (such as ethanol, cream or ointment) to the skin of the patient once a day or as needed, until the symptoms (e.g., rash or itch) are reduced or completely ameliorated.
Kits
The present disclosure also includes pharmaceutical kits useful, for example, in the treatment of disorders, diseases and conditions referred to herein, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for
mixing the components, can also be included in the kit. The kit may optionally include an additional therapeutic agent as described herein.
Combinations
The compounds of the present disclosure can be used in combination with at least one medication or therapy useful, e.g., in treating or alleviating symptoms of inflammatory skin disease. Suitable examples of such medications include corticosteroids, calcineurin inhibitors, or antibacterial or antifungal agents if the skin inflammation was caused by infection. For example, the additional agent may be hydrocortisone, cortisone, prednisone, betamethasone, tixocortol, prednisolone, methylprednisolone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, beclometasone, dexamethasone, fluocortolone, halometasone, mometasone, clobetasol, halobetasol, diflorasone, or fluticasone, or a pharmaceutically acceptable salt thereof. The second agent may also be an NSAID (e.g., administered orally), such as ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, aspirin, or indomethacin, or a pharmaceutically acceptable salt thereof. The compound of the present disclosure may be administered to the patient simultaneously with the additional therapeutic agent (in the same pharmaceutical composition or dosage form or in different compositions or dosage forms) or consecutively (the additional therapeutic agent may be administered in a separate pharmaceutical composition or dosage form before or after administration of the compound of the present disclosure).
Definitions
As used herein, the term "about" means "approximately" (e.g., plus or minus approximately 10% of the indicated value).
At various places in the present specification, substituents of compounds of the disclosure are disclosed in groups or in ranges. It is specifically intended that the disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term “Ci-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, or Ce alkyl group in the alternative. The term “C1-6 alkyl” does not encompass a mixture of compounds with variable alkyl groups within the indicated range.
As used herein, “Cn-m alkenyl” refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. The “alkyl” refers to hydrocarbon group that may be straight- chain or branched, including isomethyl or anteisomethyl branched alkyls. For example, the alkyl group may include one double carbon-carbon bond. In another example, the alkyl group may include two double carbon-carbon bonds (e.g., conjugated or unconjugated). In some examples, n can be from 19 to 60, from 19 to 40, from 19 to 37, from 20 to 60, from 20 to 40, from 20 to 37, from 21 to 60, from 21 to 40, from 21 to 37, from 22 to 60, from 22 to 40, from 22 to 37, from 23 to 60, from 23 to 40, from 23 to 37, from 23 to 60, from 23 to 40, from 23 to 37, from 24 to 60, from 24 to 40, from 24 to 37, from 25 to 60, from 25 to 40, from 25 to 37, from 26 to 60, from 26 to 40, from 26 to 37, from 27 to 60, from 27 to 40, from 27 to 37, from 28 to 60, from 28 to 40, from 28 to 37, from 29 to 60, from 29 to 40, from 29 to 37, from 30 to 60, from 30 to 40, or from 30 to 37. In some examples, m can be from 28 to 60, from 28 to 40, from 28 to 37, from 29 to 60, from 29 to 40, from 29 to 37, from 30 to 60, from 30 to 40, from 30 to
37, from 31 to 60, from 31 to 40, from 31 to 37, from 32 to 60, from 32 to 40, from 32 to
37, from 33 to 60, from 33 to 40, from 33 to 37, from 34 to 60, from 34 to 40, from 34 to
37, from 35 to 60, from 35 to 40, or from 35 to 37. While the alkyl length for any given formulation can vary as outlined above based on the CD1 isoform and tissue targeted, individual therapeutic doses will typically contain compounds with only one kind of optimized alkyl chain length.
The term “compound” as used herein is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted, as well is isotopic variants, such as those including one or more isotopes at higher than natural abundance (e.g., deuterium and/or 13C). Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified. Known CD la ligands can have isomethyl or anteisomethyl branched alkane structures that promote CD la binding.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic
forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, N=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure . Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated or synthesized as a mixture of isomers or as separated isomeric forms. In some embodiments, the compound has the ^-configuration. In some embodiments, the compound has the (^-configuration.
Compounds provided herein also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H- imidazole, 1H-, 2H- and 4H- 1 ,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H- pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.
As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” the CD1 protein with a compound of the disclosure includes the administration of a compound of the present disclosure to an individual or patient, such as a human, having CD1 protein, as well as, for example, introducing a compound of the disclosure into a sample containing a cellular or purified preparation containing the CD1.
As used herein, the term “individual,” “patient,” or “subject” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase “effective amount” or “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
As used herein the term “treating” or “treatment” refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
As used herein, the term “preventing” or “prevention” of a disease, condition or disorder refers to decreasing the risk of occurrence of the disease, condition or disorder in a subject or group of subjects (e.g., a subject or group of subjects predisposed to or susceptible to the disease, condition or disorder). In some embodiments, preventing a disease, condition or disorder refers to decreasing the possibility of acquiring the disease, condition or disorder and/or its associated symptoms. In some embodiments, preventing a disease, condition or disorder refers to completely or almost completely stopping the disease, condition or disorder from occurring.
OTHER EMBODIMENTS
It is to be understood that while the present application has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the present application, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
EXAMPLES
Many published papers have previously identified naturally occurring CD1 proteins and ligands, including natural ligands that block CD1 interaction with T cell receptors. The exemplified compounds herein are synthetically engineered non-natural lipids that block T cell receptor binding and T cell inflammatory response.
Example 1 - Synthesis of compounds
General Procedures for Chemical Analyses:
NMR spectra were recorded at 400 MHz or 300 MHz, using Bruker AV 400 and Bruker AV 300 spectrometers. Proton- decoupled 13C NMR spectra were recorded at 100 MHz using a Bruker AV 400 spectrometer. Chemical shifts are reported as 5 values (ppm) referenced to the following solvent signals: CHCh, 5H 7.26; CDCh, 5c 77.0; CH3OH, 5H 3.34; CD3OD, 5c 49.9. When a 2: 1 mixture of CDCh and CD3OD was used as solvent, chemical shifts are reported referenced to the following solvent signals: CH3OH, 5H 3.34; CD3OD, 5c 49.9. Mass spectra were recorded on a liquid chromatography time-of-flight (LCT) spectrometer utilizing electrospray ionization with a methanol mobile phase and are reported as (m/z (%)). HRMS were recorded on a Micromass LCT spectrometer using a lock mass incorporated into the mobile phase. All reagents were obtained from commercial sources and were used without further purification, unless stated otherwise. Anhydrous solvents were purchased from Sigma- Aldrich, UK, and stored over 4 A molecular sieves and under an argon atmosphere. Analytical thin layer chromatography (TLC) was performed on aluminium plates pre-coated with Merck silica gel 60A F-254 as adsorbent. The developed plates were air-dried, visualized by UV detection (at 254 nm) and/or stained with 5% phosphomolybdic acid in EtOH (MPA spray). Compounds were purified by flash column chromatography on Merck silica gel (particle size 40-63 pm mesh) or Fluka 60 (40-60 pm mesh) silica gel.
The compounds of Formula I of the disclosure can be prepared according to Scheme 1 and further described below.
Scheme 1
Step A: General procedure for the C-alkylation of acetylide anions with □- bromocarboxylic acids to yield chain-extended carboxylic acids with internal alkyne group (-ynoic acids) n-Butyl lithium (2.5 M hexane solution, 2.5 mmol, 2.5 eq) was added dropwise to a stirring solution of the terminal alkyne (1 mmol) in anhydrous tetrahydrofuran at -78 °C
under an Ar atmosphere. The reaction mixture was allowed to warm up to -20 °C over an hour. A solution of the respective co -bromocarboxylic acids (0.8 mmol, 0.8 eq) in a mixture of HMPA:THF (1:5) (10 ml) was then added dropwise over 10 minutes at -20 °C. The reaction mixture was allowed to gradually warm up to room temperature and stirred overnight. The reaction was then cooled to 0 °C before being quenched by adding saturated aqueous ammonium chloride (20 mb). The biphasic mixture was stirred vigorously for 10 minutes and then taken up in H2O (100 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography using hexanes: EtOAc (3: 1) as eluent to yield the -ynoic acid.
Step B: General procedure for the hydrogenation of the internal alkyne in the -ynoic acid to yield internal cis-alkene in the -enoic acid.
Lindlar’s catalyst (0.25 mmol, 0.25 eq) was added to a solution of the -ynoic acids (1 mmol) in anhydrous diethyl ether (50 mL) containing 0.5 mL of quinoline. The reaction mixture was degassed, flushed with H2 gas and allowed to stir under a H2 atmosphere overnight. The mixture was then filtered over Celite and the filtrate was concentrated in vacuo to give a residue that was purified by flash chromatography using EtOAc (3:1) as eluent to yield the -enoic acid.
Step C: General procedure for the synthesis of TV-hydroxysuccinimide (NHS) ester of the -enoic acids (Intermediates 11-20).
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) (105 mg, 0.55 mmol, 1.1 eq), A-hydroxysuccinimide (70 mg, 0.60 mmol, 1.2 eq) and 4-dimethylaminopyridine (10% of acid weight) were added to a solution of the -enoic acid (0.50 mmol) in anhydrous DCM (10 mL). The resulting solution was heated at 40 °C for 4 h. Upon completion of the reaction, the solution was diluted with DCM (20 mL) and washed sequentially with H2O (20 mL) and brine (20 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography using EtOAc (4: 1) as eluent to yield the NHS activated -enoic acid.
Synthesis of intermediate 11
Prepared following general procedures 1, 2 and 3 using 1 -dodecyne (168 mg, 1 mmol) and 8-bromooctanoic acid (180 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white foam after purification (196 mg, 60%). 'H NMR (CDCh): 5 5.30-5.39 (H-9, H-10, 2H, t, J=5.6Hz), 2.79-2.88 (H-2’, H-3’, 4H, m), 2.56-2.64 (H-2, 2H, m), 1.15-2.06 (H-3- H-8, H-l l- H-19, 30H, m), 0.83-0.91 (H-20, 3H, t, J=6.9Hz). 13C NMR (100 MHz, CDCh): 128.70, 128.62 (C-9, C-10), 28.55-32.81 (C-2’, C-3’, C-2, C-8, C-l l), 23.33-29.70 (multiple signals C3 - C-8, C-12 - C-19), 12.87 (C-20); MS (TOF ES+) m/z 430.3 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C24H4iNO4[M+Na]+: 430.3036, found 430.3039.
Synthesis of intermediate 12.
Prepared following general procedures 1, 2 and 3 using 1 -decyne (139 g, 1 mmol) and 10-bromodecanoic acid (205 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white foam after purification (212 mg, 65%). 'H NMR (CDCh): 5 5.28-5.39 (H-l 1, H-12, 2H, t, J=5.7Hz), 2.75-2.91 (H-2’, H-3’, 4H, m), 2.55-2.65 (H-2, 2H, m), 1.15-2.06 (H-3- H-10, H-13- H- 19, 30H, m), 0.83-0.90 (H-20, 3H, t, J=6.9Hz). 13C NMR (100 MHz, CDCh): 130.60, 129.72 (C-l l, C-12), 28.65-31.95 (C-2’, C-3’, C-2, C-10, C-13), 23.03-29.50 (multiple signals C3 - C-9, C-14 - C-19), 12.17 (C-20); MS (TOF ES+) m/z 430.3 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C24H4iNO4[M+Na]+: 430.3036, found 430.3033.
Synthesis of intermediate 13
Prepared following general procedures 1, 2 and 3 using 1 -tetradecyne (196 mg, 1 mmol, 4.0 eq.) and 8-bromooctanoic acid (175 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white foam after purification (210 mg, 60%). 'H NMR (CDCh): 5 5.35 (H-9, H-10, 2H, t, J=5.8Hz), 2.66-2.89 (H-2’, H-3’, 4H, m), 2.53-2.66 (H-2, 2H, m), 1.05-2.16 (H-3- H-7, H-12- H-21, 34H, m), 0.85 (H-22, 3H, t, J = 7.1Hz). 13C NMR (100 MHz, CDCh): 132.30, 131.72 (C- 9, C-10), 28.55-32.16 (C-2’, C-3’, C-2, C-8, C-l l), 23.05-26.80 (multiple signals C3 - C- 7, C-12 - C-21), 12.33 (C-22); MS (TOF ES+) m/z 458.3 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C26H45NO4[M+Na]+: 458.3349, found 458.3345.
Synthesis of intermediate 14
Prepared following general procedures 1, 2 and 3 using 1 -dodecyne (163 mg, 1 mmol) and 10-bromodecanoic acid (196 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white foam after purification (198 mg, 56%). 3H NMR (CDCh): 5 5.13 (H-l l, H-12, 2H, t, J= 6.2 Hz), 2.65- 2.93 (H-2’, H-3’, 4H, m), 2.58-2.72 (H-2, 2H, m), 1.02-2.18 (H-3-H-9, H-14-H-21, 34H, m), 0.88 (H-22, 3H, t, J = 6.9 Hz). 13C NMR (100 MHz, CDCh): 131.7, 130.12 (C-11, C- 12), 28.56-33.05 (C-2’, C-3’, C-2, C-10, C-13), 23.01-26.53 (multiple signals C3 - C-9, C-14 - C-21), 11.93 (C-22); MS (TOF ES+) m/z 458.3 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C26H45NO4[M+Na]+: 458.3349, found 458.3352.
Synthesis of intermediate 15
Prepared following general procedures 1, 2 and 3 using 1 -decyne (141 mg, 1 mmol) and 12-bromododecanoic acid (221 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white foam after purification (223 mg, 65%). 'H NMR (CDCh): 5 5.21 (H-13, H-14, 2H, t, J= 5.9 Hz), 2.56- 2.87 (H-2’, H-3’, 4H, m), 2.55-2.70 (H-2, 2H, m), 1.13-2.21 (H-3-H-11, H-16-H-21, 34H, m), 0.89 (H-22, 3H, t, J = 6.7 Hz). 13C NMR (100 MHz, CDCh): 132.17, 131.88 (C-13, C- 14), 28.67-32.78 (C-2’, C-3’, C-2, C-12, C-15), 23.11-27.02 (multiple signals C3 - C-l l, C-16 - C-21), 12.13 (C-22); MS (TOF ES+) m/z 458.3 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C26H45NO4[M+Na]+: 458.3349, found 458.3351.
Synthesis of intermediate 16
Prepared following general procedures 1, 2 and 3 using 1 -tetradecyne (198 mg, 1 mmol) and 10-bromodecanoic acid (203 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as a white foam after purification (212 mg, 57%). 1 H NMR (CDCh): 5 5.36 (H-l 1, H-12, 2H, t, J=5.6 Hz), 2.68- 2.72 (H-2’, H-3’, 4H, m), 2.53 (H-2, 2H, t, J=7.4 Hz), 1.98-2.07 ( H-10, H-13, 4H, m), 1.08-1.72 (H-3- H-l 9, H-14-H-23, 34 H, m), 0.80 (H-24, 3H, t, J=6.9 Hz). 13C NMR (100 MHz, CDCh): 128.13, 128.02, (C-l l, C-12), 28.01-35.61 (C-2’, C-3’, C-2, C-10, C-13), 18.05-27.12 (multiple signals C3-C-9, C-14 - C-23), 13.12 (C-24); MS (TOF ES+) m/z 486.4 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C28H49NO4[M+Na]+: 486.3662, found 486.3665.
Synthesis of intermediate 17
Prepared following general procedures 1, 2 and 3 using 1-dodecyne (165 mg, 1 mmol) and 12-bromododecanoic acid (220 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as a white foam after purification (231 mg, 62%). 'H NMR (CDCh): 5 5.51 (H-13, H-14, 2H, t, J=5.7 Hz), 2.66- 2.71 (H-2’, H-3’, 4H, m), 2.57 (H-2, 2H, t, J=7.4 Hz), 2.11-2.25 ( H-12, H-15, 4H, m), 1.05-1.70 (H-3- H-l l, H-16- H-23, 34 H, m), 0.82 (H-24, 3H, t, J = 7.2 Hz). 13C NMR (100 MHz, CDCh): 128.11, 127.97, (C-13, C-14), 28.00-35.55 (C-2’, C-3’, C-2, C-12, C- 15), 17.98-27.11 (multiple signals C3-C-11, C-16 - C-23), 13.17 (C-24); MS (TOF ES+) m/z 486.4 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C28H49NO4[M+Na]+: 486.3662, found 486.3659.
Synthesis of intermediate 18
Prepared following general procedures 1, 2 and 3 using 1-dodecyne (168 mg, 1 mmol) and 14-bromotetradeanoic acid (250 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as a white powder after purification (252 mg, 64%). 'H NMR (CDCh): 5 5.38 (H-15, H-16, 2H, t, J=5.6 Hz), 2.70- 2.76 (H-2’, H-3’, 4H, m), 2.55 (H-2, 2H, t, J=7.5 Hz), 2.02-2.15 ( H-14, H-17, 4H, m), 1.10-1.72 (H-3- H-13, H-18-H-25, 38 H, m), 0.80 (H-26, 3H, t, J=7.1 Hz). 13C NMR (100 MHz, CDCh): 128.61, 128.12, (C-17, C-18), 28.05-35.12 (C-2’, C-3’, C-2, C-14, C-17), 18.55-27.92 (multiple signals C3-C-13, C-18 - C-25), 13.51 (C-26); MS (TOF ES+) m/z 514.39 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C3oH53N04[M+Na]+: 514.3975, found 514.3972.
Synthesis of intermediate 19
Prepared following general procedures 1, 2 and 3 using 1 -decyne (136 mg, 1 mmol) and 16-bromohexadecanoic acid (270 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as a white powder after purification (245 mg, 59%). 'H NMR (CDCh): 5 5.30-5.39 (H-17, H-18, 2H, t, J=5.6 Hz), 2.71-2.82 (H-2’, H-3’, 4H, m), 2.53 (H-2, 2H, t, J=7.5 Hz), 2.08-2.22 ( H-16, H-19, 4H, m), 1.12-1.75 (H-3- H-15, H-20- H-25, 38 H, m), 0.81 (H-26, 3H, t, J=6.9Hz). 13C NMR (100 MHz, CDCh): 128.70, 128.62, (C-17, C-18), 28.55-35.02 (C-2’, C-3’, C-2, C-16, C- 19), 18.53-28.1 (multiple signals C3-C-15, C-20 - C-25), 13.47 (C-26); MS (TOF ES+) m/z 514.39 ([M + Na]+,100%); HRMS (TOF ES+) calcd for C3oH53N04[M+Na]+: 514.3975, found 514.3977.
Prepared following general procedures 1, 2 and 3 using 1 -dodecyne (164 mg, 1 mmol) and 16-bromohexadecanoic acid (266 mg, 0.8 mmol, 0.8 eq.). The title compound was obtained as an off-white powder after purification (245 mg, 59%). 'H NMR (CDCh): 5 5.30-5.39 (H-17, H-18, 2H, t, J=5.4 Hz), 2.82-2.86 (H-2’, H-3’, 4H, m), 2.60-2.65 (H-2, 2H, t, J=7.5 Hz), 1.98-2.10 ( H-16, H- 19, 4H, m), 1.05-1.54 (H-3- H- 15, H-20-H-27, 42H, m), 0.82-0.89 (H-28, 3H, t, J=6.9Hz). 13C NMR (100 MHz, CDCh): 127.80, 128.82 (C-17, C-18), 28.75-33.18 (C-2’, C-3’, C- 2, C-16, C-19), 20.53-27.90 (multiple signals C3 - C-15, C-20 - C-27), 12.87 (C-28); MS (TOF ES+) m/z 537.46 ([M + NH4]+,100%); HRMS (TOF ES+) calcd for C32H57NO4[M+NH4]+: 537.4631, found 537.4637.
Step D: General procedure for the acylation of lyso-sphingomyelin with the NHS ester of the -enoic acids from general procedure (3) to yield the desired sphingomyelin compounds 1-10.
To a solution of lyso sphingomyelin (20 mg, 0.04 mmol) in pyridine:H2O (9: 1, 2 mL) the NHS activated -enoic acid (0.08 mmol, 2 eq) was added and the solution stirred overnight at 60 °C. Upon completion of the reaction, indicated by TLC analysis, the reaction mixture was concentrated under vacuo to give a residue that was purified by flash chromatography (gradient from CHCh to 35% MeOH in CHCI3) to yield the acylated target compound as a white solid.
Synthesis of compound 1
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 11 (33 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (22 mg, 73%). MS (TOF ES+) m/z '15'1.6 ([M + H]+,100%); HRMS (TOF ES+) calcd for C43H85N2O6P[M+H]+: 757.6145, found 757.6147.
Synthesis of compound 2
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 12 (31 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (19 mg, 62%). MS (TOF ES+) m/z757.6 ([M + H]+,100%); HRMS (TOF ES+) calcd for C43H85N2O6P[M+H]+: 757.6145, found 757.6142.
Synthesis of compound 3
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 13 (35 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (21 mg, 67%). MS (TOF ES+) m/z 785.7 ([M + H]+,100%); HRMS (TOF ES+) calcd for C45H89N2O6P[M+H]+: 785.6458, found 785.6455.
Synthesis of compound 4
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 14 (35 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (20 mg, 63%). MS (TOF ES+) m/z 785.7 ([M + H]+,100%); HRMS (TOF ES+) calcd for C45H89N2O6P[M+H]+: 785.6458, found 785.6460.
Synthesis of compound 5
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 15 (35 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (18 mg, 57%). MS (TOF ES+) m/z 785.7 ([M + H]+,100%); HRMS (TOF ES+) calcd for C45H89N2O6P[M+H]+: 785.6458, found 785.6462.
Synthesis of compound 6
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 16 (37 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (22 mg, 67%). MS (TOF ES+) m/z 813.69 ([M + H]+,100%); HRMS (TOF ES+) calcd for C47H93N2O6P[M+H]+: 813.6865, found 813.6850.
Synthesis of compound 7
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 17 (38 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (19 mg, 58%). MS (TOF ES+) m/z 813.69 ([M + H]+,100%); HRMS (TOF ES+) calcd for C47H93N2O6P[M+H]+: 813.6861, found 813.6850.
Synthesis of compound 8
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 18 (40 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (21 mg, 62%). MS (TOF ES+) m/z 841.71 ([M + H]+,100%); HRMS (TOF ES+) calcd for C49H97N2O6P[M+H]+: 841.7184, found 841.7188.
Synthesis of compound 9
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 19 (41 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (18 mg, 54%). MS (TOF ES+) m/z 841.71 ([M + H]+,100%); HRMS (TOF ES+) calcd for C49H97N2O6P[M+H]+: 841.7182, found 841.7177.
Synthesis of compound 10
Prepared following general procedure 4 using lyso-sphingomyelin (20 mg, 0.04 mmol) and intermediate 20 (42 mg, 0.08 mmol, 2 eq). The title compound was obtained as an off- white powder after purification (21 mg, 60%). MS (TOF ES+) m/z 869.7 ([M + H]+,100%); HRMS (TOF ES+) calcd for C5IHIOIN206P[M+H]+: 869.7476, found 869.7479.
Example 2 - in vitro testing of sphingomyelin blocker
Previous work (J. Exp. Med., 2021, 218, 7, e20202699) showed that natural sphingomyelin with a long C42 chain length and two unsaturations (42:2 SM):
(42:2 SM 24:1 Al 5) blocked CDla-T cell receptor binding as measured in vitro by CD la tetramer binding to human T cells with a defined T cell receptor. In sharp contrast, a shorter chain 36:2 SM:
(36:2 SM 18:1 A9) did not block binding. In addition, the doubly unsaturated C42:2 compound blocked better than the singly unsaturated C42: 1 compound.
Without being bound by any particular theory or speculation, it is considered that the longer C42:2 SM lipid allows the phosphocholine head group of the lipid to protrude broadly from CDla to block approaching T cell receptors (See FIGs 2 and 3). The second unsaturation in the fatty acyl unit is buried deep within the CDla pocket, where it serves to kink the acyl chain so that it curves to bind more efficiently within the pocket leading to higher potency action (FIG. 3, arrow pointing to unsaturation).
Generally, naturally occurring cellular sphingomyelins within mammalian cells occur as mixtures, and they are most commonly C34-C36 but can range up to C42 in length. However, the sphingomyelins preferentially eluted from CDla trended strongly towards the rare C42 sphingomyelins with two unsaturations, indicating that chain length >C36 and unsaturation > 1 can increase CDla binding efficiency. The data provided in this example advantageously and unexpectedly showed that synthetic sphingomyelins with particularly long chain length have better binding to CDla in cells as compared to mixtures of diverse sphingomyelins with diverse chain lengths or defined molecules that recapitulate the most commonly occurring natural chain lengths in the range of C34-C36. As shown in FIG. 3, longer chain lipids bind within CDla, such that the longer lipids for the choline head group to more extensively protruding from within CDla, which blocks T cell receptor approach and binding to CDla. Therefore, these long chain non- natural compounds were shown to be effective blockers of CDla binding to TCRs in CDla tetramer assays using human CD la- reactive T cells based on the effects of their long chain length to generate ligand protrusion. The synthetic sphingomyelin ligands are provided in Table 1 above.
The exemplified compounds were prepared in accordance with the synthetic scheme shown in Scheme 1. Chain length, position of unsaturation, chemical formula, and exact mass for exemplified synthetic sphingomyelins are summarized in Table 2.
All compounds contain Cl 8: 1 sphingosine coupled to monounsaturated fatty acyl units ranging from C20 to C28, so that the overall combined length of the sphingosine and fatty acyl chains ranged from C38 to C46, so that they are longer than the most common natural sphingomyelins (C34-C36). The fatty acyl units were synthesized from defined precursors that allowed unsaturation to be placed at differing positions in the acyl chain from C9 (A9) to C17 (Al 7) (See Scheme 1). As the data showed, the position of double bond in the fatty acid affected CD la binding, since it is inserted inside the CD la cleft (FIG. 2).
The degree of inhibition for CD la protein binding to T cells expressing receptors that normally bind to CD la was tested for the exemplified compounds 1-10 (see Figure 5). Increased chain length contributed to blockade in all cases, and the non-natural
positioning of the second unsaturation in the fatty acyl unit affected blockade. More blockade was seen when the unsaturation was generated in positions more distal to the head group located at positions 15-17 (zll5, l 7). The strongest blockade among these newly synthesized compounds was with the longest lipid, C46:2 SM AVI (also known as compound 10), which is longer than most or all naturally occurring sphingomyelins. Also the somewhat improved blocking of C44A15 SM as compared to C44A17 SM suggests that efficacy of compound 10 (C46A17 SM) can be further improved by moving the unsaturation more proximally to create C46A15 SM. Accordingly, additional SM blockers include those with increased length of alkyl chains beyond C46, where the unsaturation is moved to more proximal positions in the fatty acyl chain and the number of unsaturations in the fatty acid chain is increased. Also, the compounds contain terminal or near terminal alkane branches (isomethyls or anteisomethyls) in the fatty acyl chains.
In contrast, naturally occurring mixtures of endogenous lipids in CD la (FIG. 5, 'mock') with varied chain length and head groups do not block T cell binding. Also, the commonly occurring short chain sphingomyelin ligands in the range of C34-38 had little blocking or slight augmentation of CDla binding to T cells (Fig. 5). Thus, the data showed that long chain length is an essential component of the blocking response and the position of the unsaturation affects response. Also, mixed sphingomyelins or mixed lipids, as found in natural lipid preparations known as CD 1 -endogenous lipids (CD1- endo), cause activation rather than blockade of T cells in published studies.
Overall, the natural cellular lipids are not suitable for use as T cell inhibitory drugs because they are present in trace amounts (nanograms) in cells, contain mixtures of short chain T cell agonists and long chain T cell antagonists, and do not represent the full spectrum of the kinds of synthetic lipids that would bind CD1 and T cell receptors. In contrast, pure lipids synthesized with long chain length and headgroup distal unsaturations strongly blocked CDla binding to T cell receptors, as well as inflammation, and terminal methyl branching in fatty acids can influence lipid binding to CDla, so blockers can contain distal alkyl branching patterns.
The most advanced prototype of a CD1 blocker compound is a synthetic lipid designated here as C46:2 Al 7 sphingomyelin (compound 10). As the experimental data in
this example shows, this compound strongly blocked CD la binding to human T cell receptors in vitro. As shown in the following Example 2, formulated in ethanol and applied to human CD la expressing mice, compound 10 reduced skin swelling and cellular inflammation in vivo in a model of psoriasiform inflammation. Strong inflammation was seen only in CD la transgenic mice, and the structure-function analysis shows a correlation between CDla-T cell receptor blockade in vitro with human T cells and therapeutic response in the skin. Thus, the data support that the mechanism of action occurs specifically via CD la and T cell response, suggesting that unwanted side effects seen with steroids and other broadly acting T cell reagents might be lacking in CD la blocking lipids.
Example 3 - Formulation of sphingomyelin blockers for topical administration
CD la is normally expressed on Langerhans cells in the epidermal layer of human skin. Because mice do not express CD la, the in vivo experiments were conducted with a human CD la knock-in mouse. CD la is non-polymorphic, and about 1 percent of human skin T cells stain with CD la tetramers suggesting the presence of large skin resident populations in vivo. The lipids of this disclosure block CD la binding to several T cell clones in vitro and also more broadly block the response of larger populations of polyclonal T cells that recognize CD la in vivo, leading to decreased inflammation in the skin.
Synthetic long (C46:2 SMA17, compound 10), intermediate (C42:2A15 SM) and short chain (C34:l SM) sphingomyelins were compared for inflammatory response. Unlike natural preparations that contain mixtures of short and long chain lipids, these experiments used pure synthetic lipids to titrate CD la binding and inhibition of immune response. The functional requirements for the delivery vehicle are that it must: 1) dissolve amphipathic lipids, 2) be safe, immunologically unreactive, and non-toxic to skin and 3) create a lipid film that can subsequently penetrate to the epidermal layers, where CD la is normally located in human skin and in the skin of CD la transgenic mice. In this experiment, ethanol was chosen which is a chemically simple, safe and effective vehicle; however, other vehicles can also be used.
A widely used model of psoriasiform and dermatitic inflammation induced by Aldara cream, whose active ingredient is a toll-like receptor 7 agonist (imiquimod), was
used in this example. Experiments were carried out in which lipid antagonists were applied to the skin of human CD la transgenic mice in an ethanol carrier, which dried rapidly, leaving a lipid film on the skin. A significant reduction in ear swelling was observed, as a global measure of inflammation and psoriasiform and dermatitic disease when long chain sphingomyelins were applied before (data not shown) or simultaneously with Aldara treatment (FIGs. 7-11).
Two controls indicate that the immunological effects are mediated by CD la, rather than some general emollient effect of lipid application to the skin. First, no immune response was seen in wild type mice lacking CD la. Second, the negative control, C34:l SM, which is not a T cell receptor blocker in tetramer assays, but serves a negative control for skin softening or other non-specific effects of sphingomyelin lipids, showed no statistically significant effects on ear thickening and fewer effects in the measurements of cellular and cytokine response.
Images of treated skin (Fig. 8) confirmed the patterns seen in ear thickness measurements and detection of cellular inflammation in the skin. Reduced inflammatory lesions were observed in skin treated with C42:2 SM and C46:2 SM as compared to short chain C34: 1 SM (FIG. 8) with the strongest effects seen with C46:2, which showed significantly reduced skin inflammation. High numbers of resident lymphocytes normally present in uninflammed skin so, as expected, treatments did not broadly reduce key resident cell populations, but there were some reductions in total T cell, neutrophil and eosinophil counts in ear skin and draining lymph node (FIG. 9A). Instead, the in vitro experimental data point to a likely reduction in T cell activation (rather than total numbers). Consistent with this expectation, surface markers of T cell activation (CD69) and skin cytokines that are normally released during activation, including ILloc, IFN-y, IL-ip, IL-6, IL17oc, IL-17f, TNFoc and most strikingly, IL-22, showed significant decreases in mice treated with compound SM46:2 (FIG. 9B). Also, although the immune stimulus was initiated in the skin, systemic measures of immune response, including plasma cytokines IFNP, IL-4, IL17oc, (FIG. 10) were significantly reduced by C46:2 SM. In addition, other cytokine reductions were apparent in mice treated with synthetic SMs that did not reach statistical significance in these experiments with small group numbers.
These trend changes were consistent with broad reduction in skin and systemic inflammation.
Overall, the small but detectable cellular changes were supported by data showing a strong and wide impact on skin and plasma cytokine pathways including members of type 1, type 2 and type 17/22 families with relevance for many human skin inflammatory diseases and systemic associations (FIG. 10). In particular, IFNy, IL-4, IL- 17, IL-22, ILip and TNFoc have proven roles in T cell mediated skin disease or have been successfully targeted with biological therapies in human skin disease. Perhaps the most useful general and objective indicator of inflammation is overall ear thickening (FIG. 7) and visible skin change (FIG. 8), which were most significantly inhibited by compound 10, as compared to SM preparations with shorter lipid tails.
Inhibition of CD la-mediated T cell response is not expected to hinder all forms of immune response. The data show that some cell types (FIG. 8), local cytokines (FIG. 9) and systemic responses (FIG. 10) are affected more than others. The statistically significant effects of compound 10, including generally stronger effects than observed with shorter chain SMs, were seen for activation markers on T cells, as well T cell derived cytokines, IL-17a, IL-17f, IL-22, TNF-a and IL-4. These effector functions have been previously associated with CDla-autoreactive T cells in human skin diseases, including atopic dermatitis and psoriasis. Thus, particular immune outcomes observed are consistent with specific effects mediated via inhibition of CD la autoreactive rather than global immune inhibition, and they are specifically tied to the non-natural C46:2 structure of the synthetic lipid analog.
These results demonstrated efficacy of a simple ethanol-based treatment formulation providing credible evidence for broader efficacy of creams and ointments to promote penetration of the exemplified compounds to the epidermis, where CD la is localized.
A large fraction of human skin T cells are CD la autoreactive, and they are activated in psoriasis, atopic dermatitis and contact dermatitis. But there are currently no therapeutic approaches that directly target CD la binding lipid ligands. The present examples identify the molecules, molecular mechanisms and efficacy of non-natural synthetic CD la ligands in selective inhibition of CD la-dependent T cell responses in
vitro in humans and in vivo in humanized mice. The compounds of the present examples represent a fundamentally new therapeutic approach based on selective inhibition of CD1- mediated T cell responses as distinguished from MHC-peptide and other T cell responses. The experimental data provide credible evidence that the compounds are useful to treat human diseases, e.g., in which CD la has been implicated, including 1) T cell responses to sebaceous oils (squalene) that are present in common acne and acne vulgaris lesions, 2) contact dermatitis from skin creams, balsam of Peru, farnesol, poison ivy, sulfa drugs, and other contact allergens, 3) psoriatic inflammation, 4) systemic type IV hypersensitivity responses to bee, wasp, and dust mite allergens and 5) chronic atopic dermatitis. These are all major diseases for which current therapy is suboptimal or for which current therapies generate unwanted, off-target effects based on their broader mechanisms of action. The 46:2 SM (compound 10) has been produced synthetically in milligram quantities, and the basic ethanol application system has been validated to show protection from disease in an in vivo mouse model.
In order to investigate whether SM had efficacy in a different inflammatory skin model, we utilized the MC903-induced model of type 2 cytokine inflammation which has features of dermatitis in humans and prominently causes itch, a major treatable skin symptom. The MC903 -induced type 2 inflammation is amplified in the presence of hCDla (Hardman et al Nat Comms 2022). SM46:2 significantly reduced ear thickness and itching/pruritus scores below the vehicle control in the MC903-induced skin inflammatory response. Furthermore, an additional discovery was made that the SM46:2 significantly reduced ear thickness and pruritus below the wild-type mice treated with MC903 (Figure 11). These mice normally express CDld and then were engineered to express CD la. The suppression of response in wild type non-transgenic mice suggests that the SM46:2 has capacity to act as a dual blocker of hCDla and mCDld, and we have detected long chain sphingomyelins in association with CDld proteins in cells (Huang, Cell, 2023, in presss). As well as having potential therapeutic applications in diseases involving type 2 inflammation in humans, the data support utility in treating broader diseases where pruritus and itch are symptoms. CD la has not been previously linked with pruritus and so this represents a new area of biology and opens new areas for therapeutic application.
Prophetic Example 4 - Sulfatides
Sulfatides (compounds S1-S1O) have the same kinds of CD la binding lipid tails as the synthetic sphingomyelins, but carry a differing headgroup comprised of sulfate and carbohydrate rather than phosphocholine. After in vitro evidence showed that sphingomyelins can block human CD la- reactive T cell response, CD la was cocrystallized with sulfatide (FIG. 4), showing a molecular mechanism that can account for T cell blockade that is related to but somewhat different then the stearic interference mechanism for sphingomyelins (FIG. 3). In both cases CDla binding is mediated by alkyl chain interactions inside of the CDla cleft, suggesting that the length and saturation patterns observed for SMs with apply here. However, the head group of sulfatide has two proposed mechanisms for blocking TCR contact. Overlay of CD la- sulfatide shows that the large sulfate containing moiety occupied a similar space compared to the choline group of sphingomyelin, which is the blocking element for SM. This positioning suggests that the sulfo-sugar could sterically inhibit TCR approach in a manner analogous to the choline group in sphingomyelin (FIGs. 2 and 4, see Example 1). However, the sulfatide moiety also disrupts a triad of residues on the outer surface of CDla, which changes the intrinsic conformation of CDla at the site at which the TCR can bind. These structural data predict that sulfatides could be particularly broad and efficacious blockers of T cell response.
The synthesis of sulphated analogues of glycosyl ceramides S1-S1O follows the synthetic route outlined above for sphingomyelins utilizing the corresponding fatty acids generated during the chemical synthesis of the compounds above (Scheme 1).
The sulfatide headgroup is chemically grafted onto the length and saturation optimized sphingolipid tails described in example 3. The following sulfatide compounds shown in Table SI can be prepared according to analogous methods and procedures shown for sphingomyelins in Scheme 2 above.
Chain length, position of unsaturation, chemical formula, and exact mass for exemplified synthetic sulfatides are summarized in Table S2.
Claims
A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein R1 is C27-41 alkenyl comprising 1 or 2 double bonds. The compound of claim 1, wherein R1 comprises 2 double bonds. The compound of claim 1, wherein R1 comprises 1 double bond. The compound of claim 3, wherein the double bond is at C9, C11, C13, C15, Cl 7, or C19. The compound of any one of claims 1-4, wherein each double bond is in Z configuration. The compound of any one of claims 1 -4, wherein each double bond is in E configuration. The compound of any one of claims 1-6, in which the fatty acid or sphingosine chains have isomethyl or anteisomethyl branches. The compound of any one of claims 1-7, wherein the compound has formula:
or a pharmaceutically acceptable salt thereof.
The compound of claim 1, wherein the compound of Formula (I) has formula:
or a pharmaceutically acceptable salt thereof. A compound selected from any one of the following compounds:
or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition of claim 11, which is suitable for enteral, parenteral or topical application to skin or mucosa. The pharmaceutical composition of claim 11, wherein the composition is in a dosage form selected from solution, cream, ointment, lotion, and mousse. A method of preventing or treating an inflammatory disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims Ills.
The method of claim 14, wherein the inflammatory disease is selected from diabetes, rheumatoid arthritis, colitis, ulcerative colitis, asthma, allergic asthma, fatty liver disease, obesity, insulin resistance, inflammatory diseases of the liver and gut, steatohepatitis, liver inflammation, acne, autoimmune diseases, atherosclerosis, hyperlipidemia, dyslipidemia, rhinitis, conjunctivitis, oral inflammation, thyroid disease, lung disease, inflammatory bowel disease (IBD), Crohn’s disease, and chronic obstructive airways disease. The method of claim 14, wherein the inflammatory disease is an inflammatory skin disease. The method of claim 16, wherein the inflammatory skin disease is selected from pruritus, nodular prurigo, itch, atopic dermatitis, eczema, psoriasis, common acne, acne vulgaris, urticaria, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, poison ivy (urushiol) dermatitis, Balsam of Peru dermatitis, contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions (cutaneous and systemic, including to sulfa antibiotics), Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen planus, erythema multiforme, urticaria, other pruritic conditions, and other allergic and irritant skin diseases. A compound of F ormula (II) :
or a pharmaceutically acceptable salt thereof, wherein R1 is C27-41 alkenyl comprising 1 or 2 double bonds. The compound of claim 18, wherein R1 comprises 2 double bonds. The compound of claim 18, wherein R1 comprises 1 double bond.
The compound of claim 20, wherein the double bond is at C9, C11, C13, C15, C17, or C19. The compound of any one of claims 18-21, wherein each double bond is in Z configuration. The compound of any one of claims 18-21, wherein each double bond is in E configuration. The compound of any one of claims 18-23 in which the fatty acid or sphingosine chains have isomethyl or anteisomethyl branches. The compound of any one of claims 18-23, wherein the compound has formula:
The compound of claim 18, wherein the compound of Formula (II) has formula:
or a pharmaceutically acceptable salt thereof. A compound selected from any one of the following compounds:
or a pharmaceutically acceptable salt of any of the foregoing. A pharmaceutical composition comprising a compound of any one of claims 18- 27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition of claim 28, which is suitable for enteral, parenteral or topical application to skin or mucosa. The pharmaceutical composition of claim 28, wherein the composition is in a dosage form selected from solution, cream, ointment, lotion, and mousse. A method of preventing or treating an inflammatory disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 18-27, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 28- 30. The method of claim 31, wherein the inflammatory disease is selected from diabetes, rheumatoid arthritis, colitis, ulcerative colitis, asthma, allergic asthma, fatty liver disease, obesity, insulin resistance, inflammatory diseases of the liver and gut, steatohepatitis, liver inflammation, acne, autoimmune diseases, atherosclerosis, hyperlipidemia, dyslipidemia, rhinitis, conjunctivitis, oral inflammation, thyroid disease, lung disease, inflammatory bowel disease (IBD), Crohn’s disease, and chronic obstructive airways disease.
The method of claim 31, wherein the inflammatory disease is an inflammatory skin disease. The method of claim 33, wherein the inflammatory skin disease is selected from atopic dermatitis, eczema, psoriasis, common acne, acne vulgaris, urticaria, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, poison ivy (urushiol) dermatitis, Balsam of Peru dermatitis, contact dermatitis of known or unknown origin, lupus erythematosus, drug reactions (cutaneous and systemic, including to sulfa antibiotics), Stevens-Johnson syndrome, toxic epidermal necrolysis, graft vs host disease, vasculitis, palmoplantar pustulosis, scleroderma, systemic sclerosis, autoimmune blistering conditions, vitiligo, alopecia areata, alopecia universalis, alopecia totalis, lichen planus, erythema multiforme, urticaria, and other pruritic conditions, and other allergic and irritant skin diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263411971P | 2022-09-30 | 2022-09-30 | |
US63/411,971 | 2022-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024073673A1 true WO2024073673A1 (en) | 2024-04-04 |
Family
ID=90479152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/075526 WO2024073673A1 (en) | 2022-09-30 | 2023-09-29 | Modulators of cd1 protein binding to t cell receptors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024073673A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220233488A1 (en) * | 2019-05-31 | 2022-07-28 | Epax Norway As | Very long chain fatty acids for treatment and alleviation of diseases |
-
2023
- 2023-09-29 WO PCT/US2023/075526 patent/WO2024073673A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220233488A1 (en) * | 2019-05-31 | 2022-07-28 | Epax Norway As | Very long chain fatty acids for treatment and alleviation of diseases |
Non-Patent Citations (3)
Title |
---|
DATABASE PUBCHEM SUBSTANCE 25 September 2020 (2020-09-25), ANONYMOUS: "(3'-sulfo)Galbeta-Cer(d18:1/24:0)", XP093158936, Database accession no. 49703646 * |
DATABASE PUBCHEM SUBSTANCE 25 September 2020 (2020-09-25), ANONYMOUS: "SM(d18:1/24:1(15Z))", XP093158934, Database accession no. 7850650 * |
RACHEL N. COTTON, MARCIN WEGRECKI, TAN-YUN CHENG, YI-LING CHEN, NATACHA VEERAPEN, JEROME LE NOURS , DENNIS P. ORGILL, BOHDAN POMA: "CD1a selectively captures endogenous cellular lipids that broadly block T cell response", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 218, no. 7, 5 July 2021 (2021-07-05), US , XP093158939, ISSN: 0022-1007, DOI: 10.1084/jem.20202699 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022071114A (en) | Use of pufa for treating skin inflammation | |
WO2012054718A2 (en) | Treating long qt syndrome | |
EP3416651A1 (en) | C-20 steroid compounds, compositions, and uses thereof to treat traumatic brain injury (tbi), including concussions | |
JP2021513532A (en) | Steroidal derivative modulator, its manufacturing method and application | |
RU2687285C2 (en) | Retinoids and use thereof | |
JP6820312B2 (en) | Elucidation of a novel 13-series resolvin that is increased by atorvastatin and eliminates inflammation | |
JP2019523245A (en) | Ligands for orphan nuclear receptor Nur77 and uses thereof | |
EP4190782A1 (en) | Biphenyl compound as immunomodulator, preparation method therefor and application thereof | |
JP4435418B2 (en) | Novel retinoids and their use | |
WO2020143640A1 (en) | Steroid compound, and use thereof and preparation method therefor | |
JP2021525803A (en) | Cannabinoids and their use | |
JP7234151B2 (en) | Fatty acid derivatives and uses thereof | |
Harikrishnan et al. | Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (RORγt) agonists | |
JP5566392B2 (en) | Triterpenoid 2-deoxyglycoside, process for its preparation and its use as a medicament | |
JPH10502940A (en) | Dermatological use of vitamin D derivatives | |
WO2024073673A1 (en) | Modulators of cd1 protein binding to t cell receptors | |
JP5283043B2 (en) | Action-selective vitamin D receptor agonist | |
JP2006517207A (en) | Methods for reducing retinoid toxicity | |
JP2018516971A (en) | Beta-naphthoisoflavone, composition containing the same and use thereof | |
JP4699347B2 (en) | Modified retinoid compounds and uses thereof | |
CN113387945A (en) | Compound PTM-3, PTM-4, preparation method and application of preparing medicine | |
JP2022538602A (en) | AKR1C3 inhibitors and their medical uses | |
WO2017131144A1 (en) | Lithocholic acid derivative having vitamin d activity | |
WO2023103929A1 (en) | Fulvestrant derivative, and preparation method therefor and medical use thereof | |
WO2005005433A1 (en) | Therapeutic agent for hyperpotassemia and bone disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23873986 Country of ref document: EP Kind code of ref document: A1 |